

(12) STANDARD PATENT
(19) AUSTRALIAN PATENT OFFICE

(11) Application No. **AU 2013237894 B2**

(54) Title
High molecular weight heparosan polymers and methods of production and use thereof

(51) International Patent Classification(s)
C12N 15/63 (2006.01) **C12N 15/70** (2006.01)
A61K 31/715 (2006.01) **C12P 19/04** (2006.01)
C12N 15/52 (2006.01)

(21) Application No: **2013237894** (22) Date of Filing: **2013.03.29**

(87) WIPO No: **WO13/149161**

(30) Priority Data

(31)	Number	(32)	Date	(33)	Country
	61/617,952		2012.03.30		US

(43) Publication Date: **2013.10.03**

(44) Accepted Journal Date: **2018.06.21**

(71) Applicant(s)
The Board of Regents of the University of Oklahoma

(72) Inventor(s)
Deangelis, Paul L.;Pummill, Philip;Visser, Regina C.

(74) Agent / Attorney
Griffith Hack, GPO Box 4164, Sydney, NSW, 2001, AU

(56) Related Art
N J OTTO ET AL., JOURNAL OF BIOLOGICAL CHEMISTRY, (2012-01-10), vol. 287, no. 10, ISSN 0021-9258, pages 7203 - 7212+7PP
US 20080226690 A1



(51) International Patent Classification:

C12N 15/63 (2006.01) C12P 19/04 (2006.01)
C12N 15/52 (2006.01) A61K 31/715 (2006.01)
C12N 15/70 (2006.01)

(21) International Application Number:

PCT/US2013/034631

(22) International Filing Date:

29 March 2013 (29.03.2013)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/617,952 30 March 2012 (30.03.2012) US

(72) Inventors; and

(71) Applicants : DEANGELIS, Paul, L. [US/US]; 706
Sunnybrook Dr., Edmond, OK 73034 (US). PUMMILL,
Philip [US/US]; 6820 Blue Spruce Court, Oklahoma City,
OK 73120 (US). VISSER, Regina, C. [US/US]; 11812
Barton Dr., Oklahoma City, OK 73120 (US).

(74) Agent: HESTER, Kathryn, L.; Dunlap Coddling P.C.,
609 W. Sheridan, P.O. Box 16370, Oklahoma City, OK
73113 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY,

BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP,
KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI,
NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU,
RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ,
TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA,
ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments (Rule 48.2(h))
- with sequence listing part of description (Rule 5.2(a))

(54) Title: HIGH MOLECULAR WEIGHT HEPAROSAN POLYMERS AND METHODS OF PRODUCTION AND USE THEREOF

(57) Abstract: High molecular weight heparosan polymers are described, as are methods of producing and using the high molecular weight heparosan polymers.



HIGH MOLECULAR WEIGHT HEPAROSAN POLYMERS AND METHODS OF PRODUCTION AND USE THEREOF

CROSS-REFERENCE TO RELATED APPLICATIONS/INCORPORATION BY REFERENCE

STATEMENT

[0001] This application claims benefit under 35 USC 119(e) of US provisional application Serial No. 61/617,952, filed March 30, 2012. The entire contents of the above-referenced application are hereby expressly incorporated herein by reference.

STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT

[0002] N/A

BACKGROUND

[0003] 1. Field of the Inventive Concept(s)

[0004] The presently disclosed and claimed inventive concept(s) relates to methodology for the production and uses of glycosaminoglycan compositions, and more particularly, to compositions comprising an isolated heparosan polymer of high molecular weight, as well as methods of production and uses thereof.

[0005] 2. Description of the Related Art

[0006] Biomaterials (loosely defined as compounds or assemblies that are used to augment or substitute for components of natural tissues or body parts) are and will continue to be integral components of tissue engineering and regenerative medicine approaches. Complex procedures including transplants and stem cell therapies promise to enhance human health, but limited supplies of donor organs/tissues and the steep learning curves (as well as ethical debates) for pioneering approaches are obstacles. There is a growing demand for more routine applications of biomaterials, such as in reconstructive surgery, cosmetics, and medical devices. Therefore, there is a need in the art for new and improved biomaterials that may be used, for example but not by way of limitation, for dermal filler applications and for surface coatings for implanted devices.

[0007] Hyaluronan (HA), poly-L-lactic acid (poly[lactide]), calcium hydroxyapatite and collagen based products dominate the current market for biomaterials utilized in reconstructive surgery and cosmetic procedures. However, these products have a number of undesirable properties for which manufacturers and healthcare professionals are seeking improvements. These disadvantages include, but are not limited to, limited lifetime, potential for immunogenicity and/or allergenicity, and non-natural appearance in aesthetic procedures. For enhancing biocompatibility and durability of an implanted device, HA, heparin, bovine serum albumin, pyrolytic carbon, or lipid coatings are employed to enhance biocompatibility of stents, catheters, and other implanted material devices. However, these products often cause fouling, clogging, or thrombus formation due to reactivity with the human body. Therefore, there is a need in the art for new and improved biomaterial compositions that overcome the disadvantages and defects of the prior art.

[0008] There are numerous medical applications of HA. For example, HA has been widely used as a viscoelastic replacement for the vitreous humor of the eye in ophthalmic surgery during implantation of intraocular lenses in cataract patients. HA injection directly into joints is also used to alleviate pain associated with arthritis. Chemically cross-linked gels and films are also utilized to prevent deleterious adhesions after abdominal surgery. Other researchers using other methods have demonstrated that adsorbed HA coatings also improve the biocompatibility of medical devices such as catheters and sensors by reducing fouling and tissue abrasion.

[0009] The presently claimed and disclosed inventive concept(s) overcomes the disadvantages and defects of the prior art. The presently claimed and disclosed inventive concept(s) is based on a biomaterial comprising heparosan, the natural biosynthetic precursor of heparin and heparan sulfate. This composition has numerous characteristics that provide improvements and advantages over existing products. While heparosan is very similar to HA and heparin, the molecule has greater stability within the body since it is not the natural final form of this sugar and therefore the body has no degradation enzymes or binding proteins that lead to loss of functionality. This property also reduces biofouling, infiltration, scarring and/or clotting. Heparosan is also more hydrophilic than synthetic coatings such as plastics or carbon. Finally, aside from bacterial HA, most other current filler

biomaterials are typically animal-derived, which causes concern for side effects such as allergic reactions or stimulating granulation, and such side effects will not be a concern with heparosan. Also, most naturally occurring heparosan polymers are known to have certain size ranges of molecular weight, depending on origin of the heparosan biopolymer such as the biosynthesis pathways utilized, including types of catalysts, hosts, and supporting apparatus. As is known in the art, the size distribution of the heparosan biopolymer affects its physical properties, such as viscosity, chain entanglement, and solubility. In the presently claimed and disclosed inventive concept(s), we have developed a means to produce extremely high molecular weight (MW) heparosan polymers that have higher viscosity and can be used at lower concentrations (either with or without chemical crosslinking) than the naturally occurring heparosan preparations.

The present invention as claimed herein is described in the following items 1 to 21:

1. A method for recombinantly producing a high molecular weight heparosan polymer, the method comprising the steps of:

culturing a recombinant host cell containing a nucleotide sequence encoding a *Pasteurella* heparosan synthase under conditions appropriate for the expression of the heparosan synthase; and

isolating heparosan polymer produced by the heparosan synthase, wherein the isolated heparosan polymer is biocompatible with a mammalian patient and biologically inert within extracellular compartments of a mammalian patient, and wherein the isolated heparosan polymer is represented by the structure $(-\text{GlcUA-}\beta\text{1,4-GlcNAc-}\alpha\text{1,4-})_n$, wherein n is a positive integer greater than or equal to 2,000.

2. The method of item 1, wherein culturing the recombinant host cells comprises the steps of:

culturing a recombinant host cell containing a nucleotide sequence encoding a polypeptide having heparosan synthase activity under conditions appropriate for the expression of the heparosan synthase, wherein at least one of:

(a) the polypeptide having heparosan synthase activity is at least 90% identical to at least one of SEQ ID NOS:2, 4, and 6-8, and the nucleotide sequence encoding the polypeptide has been gene-optimized for expression in the recombinant host cell;

- (b) the polypeptide having heparosan synthase activity has 1-20 amino acid additions, deletions, and/or substitutions when compared to at least one of SEQ ID NOS:2, 4, and 6-8, and the nucleotide sequence encoding the polypeptide has been gene-optimized for expression in the recombinant host cell;
- (c) the polypeptide is encoded by the nucleotide sequence of at least one of SEQ ID NOS:9-11;
- (d) the polypeptide is encoded by a nucleotide sequence that is at least 90% identical to at least one of SEQ ID NOS:9-11; and

isolating heparosan polymer produced by the heparosan synthase, wherein the isolated heparosan polymer is biocompatible with a mammalian patient and biologically inert within extracellular compartments of a mammalian patient, and wherein the isolated heparosan polymer is represented by the structure $(-\text{GlcUA}-\beta 1,4-\text{GlcNAc}-\alpha 1,4-)_n$, wherein n is a positive integer greater than or equal to 2,000.

3. The method of item 1, wherein the isolated heparosan polymer is has a value for n in a range of from about 2,000 to about 17,000.
4. The method of any one of items 1-3, further comprising attaching the isolated heparosan polymer to at least a portion of a surface of a substrate.
5. The method of item 4, wherein the substrate is selected from the group consisting of silica, silicon, semiconductors, glass, polymers, nanotubes, nanoparticles, organic compounds, inorganic compounds, metals, and combinations thereof.
6. The method of item 4, wherein at least a portion of the substrate is a metal selected from the group consisting of gold, copper, stainless steel, nickel, aluminum, titanium, thermosensitive alloys, and combinations thereof.

7. The method of any one of items 1-6, further comprising the step of crosslinking the isolated heparosan polymer.
8. The method of any one of items 1-7, wherein the recombinant host cell is an *E. coli* recombinant host cell.
9. An isolated nucleotide sequence encoding a polypeptide having heparosan synthase activity, wherein at least one of:
 - (a) the polypeptide having heparosan synthase activity is at least 90% identical to at least one of SEQ ID NOS:2, 4, and 6-8, and the nucleotide sequence encoding the polypeptide has been gene-optimized for expression in the recombinant host cell; and
 - (b) the polypeptide having heparosan synthase activity has 1-20 amino acid additions, deletions, and/or substitutions when compared to at least one of SEQ ID NOS:2, 4, and 6-8, and the nucleotide sequence encoding the polypeptide has been gene-optimized for expression in the recombinant host cell;
 - (c) the polypeptide is encoded by the nucleotide sequence of at least one of SEQ ID NOS:9-11; and
 - (d) the polypeptide is encoded by a nucleotide sequence that is at least 90% identical to at least one of SEQ ID NOS:9-11.
10. A recombinant host cell, comprising the isolated nucleotide sequence of item 9.
11. A method of augmenting tissue in a mammalian patient, comprising the steps of:
administering an effective amount of a biomaterial composition to a mammalian patient, the biomaterial composition comprising an isolated heparosan polymer that is biocompatible with the mammalian patient and biologically inert in extracellular compartments of the mammalian patient, wherein the isolated heparosan polymer is represented by the structure $(\text{-GlcUA-}\beta\text{1,4-GlcNAc-}\alpha\text{1,4-})_n$, wherein n is a positive integer greater than or equal to 2,000.

12. The method of item 11, wherein the isolated heparosan polymer has a value for n in a range of from about 2,000 to about 17,000.
13. The method of any one of items 11-12, wherein the biomaterial composition is in a gel, semi-solid, liquid, and/or particulate state.
14. The method of any one of items 11-13, wherein the biomaterial composition further comprises a substrate, and wherein the isolated heparosan polymer is attached to the substrate.
15. A biomaterial composition, the composition comprising:
an isolated heparosan polymer, wherein the isolated heparosan polymer is biocompatible with a mammalian patient and biologically inert in extracellular compartments of a mammalian patient, the isolated heparosan polymer being represented by the structure $(-\text{GlcUA}-\beta 1,4-\text{GlcNAc}-\alpha 1,4-)_n$, wherein n is a positive integer greater than or equal to 2,000.
16. The biomaterial composition of item 15, wherein n is in a range of from about 2,000 to about 17,000.
17. The biomaterial composition of any one of items 15-16, wherein the biomaterial is in a gel, semi-solid, and/or particulate state.
18. The biomaterial composition of any one of items 15-17, wherein the isolated heparosan polymer is attached to a substrate.
19. The biomaterial composition of item 18, wherein the substrate is selected from the group consisting of silica, silicon, semiconductors, glass, polymers, nanotubes, nanoparticles, organic compounds, inorganic compounds, metals, and combinations thereof.

20. The biomaterial composition of item 18, wherein at least a portion of the substrate is a metal selected from the group consisting of gold, copper, stainless steel, nickel, aluminum, titanium, thermosensitive alloys, and combinations thereof.
21. Use of a biomaterial composition of any one of items 15-20 in the manufacture of a medicament for augmenting tissue in a mammalian patient.

BRIEF DESCRIPTION OF THE DRAWINGS

[00010] Figure 1A contains an alignment of two *E. coli* gene-optimized sequences (SEQ ID NOS:9 and 10) with the native *Pasteurella multocida* heparosan synthase gene (SEQ ID NO:1).

[00011] Figure 1B contains an alignment of the two *E. coli* gene-optimized sequences (SEQ ID NOS:9 and 10).

[00012] Figure 1C contains an alignment of a *Bacillus* gene-optimized sequence (SEQ ID NO:11) with the native *Pasteurella multocida* heparosan synthase gene (SEQ ID NO:1).

[00013] Figure 2 depicts a gel analysis demonstrating the production of ultra-high molecular weight heparosan polymer in *E. coli* K5 with plasmid-borne recombinant *PmHS1* gene from *P. multocida* Type D.

[00014] Figure 3 depicts a gel analysis demonstrating the production of ultra-high molecular weight heparosan polymer in *E. coli* BL21(DE3) with either plasmid-borne recombinant *PmHS1* gene or an expression plasmid that produces a maltose-binding protein (MBP) *PmHS1* fusion protein.

[00015] Figure 4 depicts a gel analysis demonstrating the production of ultra-high molecular weight heparosan polymer in *E. coli* BL21Express I^q transformed with the expression plasmid that produces the maltose-binding protein (MBP) *PmHS1* fusion protein.

[00016] Figure 5 depicts a gel analysis demonstrating the production of ultra-high molecular weight heparosan polymer in *E. coli* K5⁻ (in which the *kfiA*, *kfiB*, and *kfiC* genes have been deleted) with either plasmid-borne recombinant *PmHS1* gene or the expression plasmid that produces the maltose-binding protein (MBP) PmHS1 fusion protein.

DETAILED DESCRIPTION

[00017] Before explaining at least one embodiment of the inventive concept(s) in detail by way of exemplary drawings, experimentation, results, and laboratory procedures, it is to be understood that the inventive concept(s) is not limited in its application to the details of construction and the arrangement of the components set forth in the following description or illustrated in the drawings, experimentation and/or results. The inventive concept(s) is capable of other embodiments or of being practiced or carried out in various ways. As such, the language used herein is intended to be given the broadest possible scope and meaning; and the embodiments are meant to be exemplary - not exhaustive. Also, it is to be understood that the phraseology and terminology employed herein is for the purpose of description and should not be regarded as limiting.

[00018] Unless otherwise defined herein, scientific and technical terms used in connection with the presently disclosed and claimed inventive concept(s) shall have the meanings that are commonly understood by those of ordinary skill in the art. Further, unless otherwise required by context, singular terms shall include pluralities and plural terms shall include the singular. Generally, nomenclatures utilized in connection with, and techniques of, cell and tissue culture, molecular biology, and protein and oligo- or polynucleotide chemistry and hybridization described herein are those well-known and commonly used in the art. Standard techniques are used for recombinant DNA, oligonucleotide synthesis, and tissue culture and transformation (e.g., electroporation, lipofection). Enzymatic reactions and purification techniques are performed according to manufacturer's specifications or as commonly accomplished in the art or as described herein. The foregoing techniques and procedures are generally performed according to conventional methods well known in the art and as described in various general and more specific references that are cited and discussed throughout the present specification. See

e.g., Sambrook et al. Molecular Cloning: A Laboratory Manual (2nd ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. (1989) and Coligan et al. Current Protocols in Immunology (Current Protocols, Wiley Interscience (1994)), which are incorporated herein by reference. The nomenclatures utilized in connection with, and the laboratory procedures and techniques of, analytical chemistry, synthetic organic chemistry, and medicinal and pharmaceutical chemistry described herein are those well known and commonly used in the art. Standard techniques are used for chemical syntheses, chemical analyses, pharmaceutical preparation, formulation, and delivery, and treatment of patients.

[00019] All patents, published patent applications, and non-patent publications mentioned in the specification are indicative of the level of skill of those skilled in the art to which this presently disclosed and claimed inventive concept(s) pertains. All patents, published patent applications, and non-patent publications referenced in any portion of this application are herein expressly incorporated by reference in their entirety to the same extent as if each individual patent or publication was specifically and individually indicated to be incorporated by reference.

[00020] All of the compositions and/or methods disclosed and claimed herein can be made and executed without undue experimentation in light of the present disclosure. While the compositions and methods of this invention have been described in terms of preferred embodiments, it will be apparent to those of skill in the art that variations may be applied to the compositions and/or methods and in the steps or in the sequence of steps of the method described herein without departing from the concept, spirit and scope of the invention. All such similar substitutes and modifications apparent to those skilled in the art are deemed to be within the spirit, scope and concept of the inventive concept(s) as defined by the appended claims.

[00021] As utilized in accordance with the present disclosure, the following terms, unless otherwise indicated, shall be understood to have the following meanings:

[00022] The use of the word “a” or “an” when used in conjunction with the term “comprising” in the claims and/or the specification may mean “one,” but it is also consistent with the meaning of “one or more,” “at least one,” and “one or more than one.” The use of the term “or” in the claims is used to mean “and/or” unless explicitly indicated to refer to

alternatives only or the alternatives are mutually exclusive, although the disclosure supports a definition that refers to only alternatives and “and/or.” Throughout this application, the term “about” is used to indicate that a value includes the inherent variation of error for the device, the method being employed to determine the value, or the variation that exists among the study subjects. The use of the term “at least one” will be understood to include one as well as any quantity more than one, including but not limited to, 2, 3, 4, 5, 10, 15, 20, 30, 40, 50, 100, etc. The term “at least one” may extend up to 100 or 1000 or more, depending on the term to which it is attached; in addition, the quantities of 100/1000 are not to be considered limiting, as higher limits may also produce satisfactory results. In addition, the use of the term “at least one of X, Y and Z” will be understood to include X alone, Y alone, and Z alone, as well as any combination of X, Y and Z.

[00023] Throughout the specification and claims, unless the context requires otherwise, the terms "substantially" and "about" will be understood to not be limited to the specific terms qualified by these adjectives/adverbs, but will be understood to indicate a value includes the inherent variation of error for the device, the method being employed to determine the value and/or the variation that exists among study subjects. Thus, said terms allow for minor variations and/or deviations that do not result in a significant impact thereto. For example, in certain instances the term “about” is used to indicate that a value includes the inherent variation of error for the device, the method being employed to determine the value and/or the variation that exists among study subjects. Similarly, the term “substantially” may also relate to 80% or higher, such as 85% or higher, or 90% or higher, or 95% or higher, or 99% or higher, and the like.

[00024] As used in this specification and claim(s), the words “comprising” (and any form of comprising, such as “comprise” and “comprises”), “having” (and any form of having, such as “have” and “has”), “including” (and any form of including, such as “includes” and “include”) or “containing” (and any form of containing, such as “contains” and “contain”) are inclusive or open-ended and do not exclude additional, unrecited elements or method steps.

[00025] The term “or combinations thereof” as used herein refers to all permutations and combinations of the listed items preceding the term. For example, “A, B, C, or

combinations thereof" is intended to include at least one of: A, B, C, AB, AC, BC, or ABC, and if order is important in a particular context, also BA, CA, CB, CBA, BCA, ACB, BAC, or CAB. Continuing with this example, expressly included are combinations that contain repeats of one or more item or term, such as BB, AAA, MB, BBC, AAABCCCC, CBBAAA, CABABB, and so forth. The skilled artisan will understand that typically there is no limit on the number of items or terms in any combination, unless otherwise apparent from the context.

[00026] The term "naturally-occurring" as used herein as applied to an object refers to the fact that an object can be found in nature. For example, a polypeptide or polynucleotide sequence that is present in an organism (including viruses) that can be isolated from a source in nature and which has not been intentionally modified by man in the laboratory or otherwise is naturally-occurring. Similarly, a sugar polymer or polysaccharide with intrinsic structural features (such as but not limited to, composition, molecular weight (MW) distribution, etc.) found in native organisms (i.e., unmodified by the hand of man) is termed "naturally occurring".

[00027] The term "patient" as used herein includes human and veterinary subjects. "Mammal" for purposes of treatment refers to any animal classified as a mammal, including human, domestic and farm animals, nonhuman primates, and any other animal that has mammary tissue.

[00028] The terms "administration" and "administering", as used herein will be understood to include all routes of administration known in the art, including but not limited to, oral, topical, transdermal, parenteral, subcutaneous, intranasal, mucosal, intramuscular, intraperitoneal, intravitreal and intravenous routes, including both local and systemic applications. In addition, the compositions of the presently disclosed and claimed inventive concept(s) (and/or the methods of administration of same) may be designed to provide delayed, controlled or sustained release using formulation techniques which are well known in the art.

[00029] The term "dermal augmentation" in the context of the presently disclosed and claimed inventive concept(s) refers to any change of the natural state of a mammal's skin and related areas due to external acts. The areas that may be changed by dermal

augmentation include, but not limited to, epidermis, dermis, subcutaneous layer, fat, arrector pill muscle, hair shaft, sweat pore, and sebaceous gland.

[00030] As used herein, the term “heparosan” will be understood to refer to the natural biosynthetic precursor of heparin and heparin sulfate. The sugar polymer heparosan is an unsulfated, unepimerized heparin molecule, and may also be referred to as “N-acetyl heparosan”.

[00031] The term “tissue” as used herein will be understood to refer to a grouping of cells within an organism that are similarly characterised by their structure and function.

[00032] The term “biomaterial” as used herein will be understood to refer to any nondrug material that can be used to treat, enhance, protect, or replace any tissue, organ, or function in an organism. The term “biomaterial” also refers to biologically derived material that is used for its structural rather than its biological properties, for example but not by way of limitation, to the use of collagen, the protein found in bone and connective tissues, as a cosmetic ingredient, or to the use of carbohydrates modified with biotechnological processes as lubricants for biomedical applications or as bulking agents in food manufacture. A “biomaterial” is any material, natural or man-made, that comprises whole or part of a living structure or biomedical device that performs, augments, protects, or replaces a natural function and that is compatible with the body.

[00033] As used herein, when the term "isolated" is used in reference to a molecule, the term means that the molecule has been removed from its native environment. For example, a polynucleotide or a polypeptide naturally present in a living organism is not "isolated," but the same polynucleotide or polypeptide separated from the coexisting materials of its natural state is "isolated." Further, recombinant DNA molecules contained in a vector are considered isolated for the purposes of the presently disclosed and claimed inventive concept(s). Isolated RNA molecules include in vivo or in vitro RNA replication products of DNA and RNA molecules. Isolated nucleic acid molecules further include synthetically produced molecules. Additionally, vector molecules contained in recombinant host cells are also isolated. Overall, this also applies to carbohydrates in general. Thus, not all "isolated" molecules need be "purified."

[00034] As used herein, when the term "purified" is used in reference to a molecule, it means that the concentration of the molecule being purified has been increased relative to molecules associated with it in its natural environment. Naturally associated molecules include proteins, nucleic acids, lipids and sugars but generally do not include water, buffers, and reagents added to maintain the integrity or facilitate the purification of the molecule being purified.

[00035] As used herein, the term "substantially purified" refers to a compound that is removed from its natural environment and is at least 60% free, preferably 75% free, and most preferably 90% free from other components with which it is naturally associated.

[00036] As used herein, "substantially pure" means an object species is the predominant species present (i.e., on a molar basis it is more abundant than any other individual species in the composition), and preferably a substantially purified fraction is a composition wherein the object species comprises at least about 50 percent (on a molar basis) of all macromolecular species present. Generally, a substantially pure composition will comprise more than about 80 percent of all macromolecular species present in the composition, such as more than about 85%, 90%, 95%, and 99%. In one embodiment, the object species is purified to essential homogeneity (contaminant species cannot be detected in the composition by conventional detection methods) wherein the composition consists essentially of a single macromolecular species.

[00037] As used herein, the term "substrate" will be understood to refer to any surface of which a coating may be disposed. Examples of substrates that may be utilized in accordance with the presently disclosed and claimed inventive concept(s) include, but are not limited to, silica, silicon, glass, polymers, nanotubes, nanoparticles, organic compounds, inorganic compounds, metals and combinations thereof. When the substrate is a metal, the metal may include, but is not limited to, gold, copper, stainless steel, nickel, aluminum, titanium, thermosensitive alloys and combinations thereof.

[00038] The terms "gel" and "semi-solid" are used interchangeably herein and will be understood to include a colloidal system, with the semblance of a solid, in which a solid is dispersed in a liquid; the compound may have a finite yield stress. The term "gel" also refers to a jelly like material formed by the coagulation of a colloidal liquid. Many gels have

a fibrous matrix and fluid filled interstices: gels are viscoelastic rather than simply viscous and can resist some mechanical stress without deformation. When pressure is applied to gels or semi-solids, they conform to the shape at which the pressure is applied.

[00039] The term "hydrogel" is utilized herein to describe a network of polymer chains that are water-insoluble, sometimes found as a colloidal gel in which water is the dispersion medium. Hydrogels are very absorbent natural or synthetic polymers, and may contain over 99% water. Hydrogels also possess a degree of flexibility very similar to natural tissue, due to their significant water content. In addition, peptides and/or larger biologically active substances can be enclosed in hydrogels, thereby forming a sustained release composition.

[00040] As used herein, the term "effective amount" refers to an amount of a biomaterial composition or conjugate or derivative thereof sufficient to exhibit a detectable therapeutic or prophylactic effect without undue adverse side effects (such as toxicity, irritation and allergic response) commensurate with a reasonable benefit/risk ratio when used in the manner of the inventive concept(s). The effective amount for a subject will depend upon the type of subject, the subject's size and health, the nature and severity of the condition to be treated, the method of administration, the duration of treatment, the nature of concurrent therapy (if any), the specific formulations employed, and the like. Thus, it is not possible to specify an exact effective amount in advance. However, the effective amount for a given situation can be determined by one of ordinary skill in the art using routine experimentation based on the information provided herein.

[00041] As used herein, the term "nucleic acid segment" and "DNA segment" are used interchangeably and refer to a DNA molecule which has been isolated free of total genomic DNA of a particular species. Therefore, a "purified" DNA or nucleic acid segment as used herein, refers to a DNA segment which contains a Heparosan Synthase (HS) coding sequence yet is isolated away from, or purified free from, unrelated genomic DNA, for example, total *Pasteurella multocida*. Included within the term "DNA segment", are DNA segments and smaller fragments of such segments, and also recombinant vectors, including, for example, plasmids, cosmids, phage, viruses, and the like.

[00042] The term "expression" as used herein may include any step involved in the production of heparosan synthases, including but not limited to, transcription and translation.

[00043] The terms "gene-optimized" and "gene optimization" as used herein refers to changes in the nucleotide sequence encoding a protein to those preferentially used in a particular host cell such that the encoded protein is more efficiently expressed in the host cell when compared to the native nucleotide sequence. Gene-optimization involves various aspects of improving codon usage and messenger RNA structure to improve protein production. It is well known in the art that genes from one organism, the source, do not always perform well in a recipient organism. For example, some amino acids (AAs) are encoded by multiple tRNAs (the degenerate code), and each organism has a preferred codon(s) that is used more frequently. If a rare codon is used in a gene, then the ribosome must stall and wait for the rare tRNA to be found before the protein translation can move onto the next amino acid to be added; if the stalling occurs too long, then the ribosome can fall off, and the protein is not made. Similarly, if the mRNA has a secondary structure that interferes with ribosome movement and thus translation, then the ribosome can fall off the messenger RNA, again resulting in less protein production. By studying the DNA sequence of naturally highly produced proteins in the desired host or recipient organism, certain codons for AAs are noted. Therefore, the source gene can be converted to a more highly functional producer if the rare codons are removed, and the more used codons (with respect to the recipient) are used. The protein sequence is the same, but the DNA sequence can differ due to the degenerate tRNA code. As there are many aspects to the translation process, there are multiple important optimization issues that need to be addressed, including but not limited to, codon usage bias, GC content, CpG dinucleotides content, mRNA secondary structure, cryptic splicing sites, premature PolyA sites, internal chi sites and ribosomal binding site, negative CpG islands, RNA instability motifs (ARE), repeat sequences (direct repeat, reverse repeat, and Dyad repeat), addition of Kozak sequences and/or Shine-Dalgarno sequences to increase the efficiency of translational initiation, addition of stop codons to increase the efficiency of translational termination, and the like.

Therefore, gene optimization, as used herein, refers to any changes in a nucleotide sequence made to address one or more of the optimization issues mentioned above.

[00044] A non-limiting example of a type of gene optimization utilized in accordance with the presently disclosed and claimed inventive concept(s) is codon optimization. The terms "codon-optimized" and "codon optimization" refers to changes in the codons of the polynucleotide encoding a protein to those preferentially used in a particular organism such that the encoded protein is efficiently expressed in the organism of interest. Although the genetic code is degenerate in that most amino acids are represented by several codons, called "synonyms" or "synonymous" codons, it is well known that codon usage by particular organisms is nonrandom and biased towards particular codon triplets. This codon usage bias may be higher in reference to a given gene, genes of common function or ancestral origin, highly expressed proteins versus low copy number proteins, and the aggregate protein coding regions of an organism's genome. In some embodiments, the polynucleotides encoding enzymes may be codon-optimized for optimal production from the host organism selected for expression.

[00045] "Preferred, optimal, high codon usage bias codons" refers interchangeably to codons that are used at higher frequency in the protein coding regions than other codons that code for the same amino acid. The preferred codons may be determined in relation to codon usage in a single gene, a set of genes of common function or origin, highly expressed genes, the codon frequency in the aggregate protein coding regions of the whole organism, codon frequency in the aggregate protein coding regions of related organisms, or combinations thereof. Codons whose frequency increases with the level of gene expression are typically optimal codons for expression. A variety of methods are known for determining the codon frequency (e.g., codon usage, relative synonymous codon usage) and codon preference in specific organisms, including multivariate analysis, for example, using cluster analysis or correspondence analysis, and the effective number of codons used in a gene (See GCG Codon Preference, Genetics Computer Group Wisconsin Package; CodonW, John Peden, University of Nottingham; McInerney, J. O, 1998, Bioinformatics 14:372-73; Stenico et al., 1994, Nucleic Acids Res. 22:2437-46; Wright, F., 1990, Gene 87:23-29). Codon usage tables are available for a growing list of organisms (see for example, Wada et al., 1992,

Nucleic Acids Res. 20:2111-2118; Nakamura et al., 2000, Nucl. Acids Res. 28:292; Duret, et al., supra; Henaut and Danchin, "Escherichia coli and Salmonella," 1996, Neidhardt, et al. Eds., ASM Press, Washington D.C., p. 2047-2066), all of which are expressly incorporated herein by reference. The data source for obtaining codon usage may rely on any available nucleotide sequence capable of coding for a protein. These data sets include nucleic acid sequences actually known to encode expressed proteins (e.g., complete protein coding sequences-CDS), expressed sequence tags (ESTs), or predicted coding regions of genomic sequences (see for example, Mount, D., Bioinformatics: Sequence and Genome Analysis, Chapter 8, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 2001; Uberbacher, E. C., 1996, Methods Enzymol. 266:259-281; Tiwari et al., 1997, Comput. Appl. Biosci. 13:263-270), all of which are incorporated herein by reference.

[00046] The Dalton (Da) is the international unit of molecular mass based on 1/12 of the mass of carbon 12. A kiloDalton (kDa) is 1,000 Da. A mega-Dalton (MDa) is 1,000 kDa.

[00047] Turning now to the presently disclosed and claimed inventive concept(s), compositions that include an isolated high molecular weight (HMW) heparosan polymer are included and described in detail herein, along with methods of producing and using same. In certain embodiments, the composition is a biomaterial composition. In particular embodiments, the isolated heparosan polymer is biocompatible with a mammalian patient and biologically inert in extracellular compartments of the mammalian patient. The heparosan polymer is substantially not susceptible to vertebrate (such as but not limited to, mammalian) hyaluronidases or vertebrate (such as but not limited to, mammalian) heparanases and thereby is not substantially degraded *in vivo* in extracellular compartments of the mammalian patient. In addition, the heparosan polymer may be recombinantly produced as described in detail herein utilizing a combination of host cell and synthase biosynthesis, where features of both of these factors influence the MW made by the live cell.

[00048] The disclosed and claimed isolated heparosan polymer is represented by the structure $(-\text{GlcUA-}\beta\text{1,4-GlcNAc-}\alpha\text{1,4-})_n$, wherein n is a positive integer greater than or equal to about 2,000. Polymers of this size are hitherto unreported in the scientific literature and prior art. Each single n unit is approximately 400 Da, and therefore the

isolated heparosan polymer has a molecular weight (MW) of greater than or equal to about 800 kDa. In particular embodiments, n is a positive integer in a range of from about 2,000 to about 17,000, and therefore the isolated heparosan polymer has a MW in a range of from about 0.8 MDa to about 6.8 MDa. In addition, n may be a positive integer such as but not limited to, 2,250; 2,500; 2,750; 3,000; 3,250; 3,500; 3,750; 4,000; 4,250; 4,500; 4,750; 5,000; 5,250; 5,500; 5,750; 6,000; 6,250; 6,500; 6,750; 7,000; 7,250; 7,500; 7,750; 8,000; 8,250; 8,500; 8,750; 9,000; 9,250; 9,500; 9,750; 10,000; 10,250; 10,500; 10,750; 11,000; 11,250; 11,500; 11,750; 12,000; 12,250; 12,500; 12,750; 13,000; 13,250; 13,500; 13,750; 14,000; 14,250; 14,500; 14,750; 15,000; 15,250; 15,500; 15,750; 16,000; 16,250; 16,500; 16,750; and 17,000; as well as within a range of any of the above.

[00049] The heparosan polymer may be linear or cross-linked. The compositions of the presently disclosed and claimed inventive concept(s) may be administered to a patient by any means known in the art; for example, but not by way of limitation, the compositions may be injectable and/or implantable. In addition, the compositions may be in a gel or semi-solid state, a suspension of particles, or the compositions may be in a liquid form.

[00050] Alternatively, the heparosan polymer may be attached to a substrate. When attached to a substrate, the isolated heparosan polymer may be covalently (via a chemical bond) or non-covalently (via weak bonds) attached to the substrate. Any substrate known in the art or otherwise contemplated herein may be utilized, so long as the substrate is capable of being attached to the heparosan polymer and functioning in accordance with the presently disclosed and claimed inventive concept(s). Examples of substrates that may be utilized in accordance with the presently disclosed and claimed inventive concept(s) include, but are not limited to, silica, silicon, semiconductors, glass, polymers, nanotubes, nanoparticles, organic compounds, inorganic compounds, metals, and combinations thereof. Non-limiting examples of metals that may be utilized include gold, copper, stainless steel, nickel, aluminum, titanium, thermosensitive alloys, and combinations thereof.

[00051] The presently disclosed and claimed inventive concept(s) also comprises biomaterial compositions comprising a cross-linked gel that includes an isolated heparosan polymer and at least one cross-linking agent. The cross-linking agent may be any cross-

linking agent known or otherwise contemplated in the art; specific non-limiting examples of cross-linking agents that may be utilized in accordance with the presently disclosed and claimed inventive concept(s) include aldehydes, epoxides, polyaziridyl compounds, glycidyl ethers, divinyl sulfones, and combinations and derivatives thereof. An advantage of the currently described inventive concept(s) is that lower concentrations of this high MW (greater than 1 MDa or 1,000 kDa) polymer may be used to produce useful gels than if a lower MW polymer was employed.

[00052] Any of the biomaterial compositions of the presently disclosed and claimed inventive concept(s) may be a moisturizing biomaterial that protects from dehydration; alternatively, any of the biomaterial compositions of the presently disclosed and claimed inventive concept(s) may be a lubricating biomaterial.

[00053] Another aspect of the presently disclosed and claimed inventive concept(s) is related to kits for *in vivo* administration of any of the compositions described herein above or otherwise contemplated herein to a mammalian patient. The kit may also include instructions for administering the composition to the mammalian patient. The kit may optionally also contain one or more other compositions for use in accordance with the methods described herein.

[00054] The presently disclosed and claimed inventive concept(s) is further directed to a method of recombinantly producing a high MW heparosan polymer. In the method, a recombinant host cell containing a nucleotide sequence encoding a heparosan synthase, the enzyme that polymerizes the monosaccharides from UDP-sugar precursors into heparosan polysaccharide or sugar polymer, is cultured under conditions appropriate for the expression of the heparosan synthase. The heparosan synthase produces the high MW heparosan polymer, which is then isolated.

[00055] The isolated high MW heparosan polymer may possess any or all of the characteristics described herein above, and may subsequently be utilized as a biomaterial composition. Thus, the method may further comprise one or more steps to this end, such as but not limited to, crosslinking the isolated heparosan polymer or attaching (either covalently or non-covalently) the isolated heparosan polymer to any of the substrates described or otherwise contemplated herein.

[00056] In certain non-limiting embodiments, the host cell is an *E. coli* host cell, and the heparosan synthase is a *Pasteurella* heparosan synthase.

[00057] Any heparosan synthase known in the art or otherwise contemplated herein may be utilized in accordance with the presently disclosed and claimed inventive concept(s), so long as the heparosan synthase is capable of producing a high MW heparosan polymer in an appropriate host under the appropriate culture conditions. Non-limiting examples of heparosan synthases that may be utilized in accordance with the presently disclosed and claimed inventive concept(s) are described in greater detail herein below.

[00058] Any host cell known in the art or otherwise contemplated herein may be utilized in accordance with the presently disclosed and claimed inventive concept(s), so long as the host cell is capable of being made recombinant with a heparosan synthase gene and producing a high MW heparosan polymer upon expression of the heparosan synthase gene under the appropriate culture conditions. Non-limiting examples of host cells that may be utilized in accordance with the presently disclosed and claimed inventive concept(s) are described in greater detail below.

[00059] In one embodiment, the presently disclosed and claimed inventive concept(s) shows that *Pasteurella* heparosan synthases (or catalyst with sequence similarity or key motifs) will perform the ultra-high MW heparosan biosynthesis operation in an *E. coli* host cell with the proper UDP-sugar and transport infrastructure. Most available *E. coli* strains employed in laboratories as well as most wild-type isolates are therefore not useful without further manipulation. The presently disclosed and claimed inventive concept(s) demonstrates that an *E. coli* K5 host (or strains that contain similar infrastructure) is amenable to high MW heparosan polymer production.

[00060] In theory, at least simple two models for controlling the size of a polymer are possible: (A) host cell-controlled biosynthesis or (B) synthase-controlled biosynthesis. In the former model, the nature of the supporting apparatus (*e.g.*, UDP-sugar precursors, transporters) defines the final size distribution made by the live cell. In the latter model, the intrinsic properties of the polymerizing catalyst (*e.g.*, elongation rate, processivity) control the polymer size distribution made by the live cell. A third model (C), combinatorial host cell/synthase biosynthesis, is possible where features of both factors influence the MW

made by a live cell; this model is also the most complex, unpredictable, and non-obvious to decipher. For the presently disclosed and claimed inventive concept(s), models A & B are inconsistent with the observed data; neither the *Escherichia coli* K5 host cell's product size (~50-80 kDa) nor the *Pasteurella* heparosan synthase product size (~100-300 kDa) is similar to the heparosan made in the inventive concept(s) (>800 kDa) and should be considered a non-predictable outcome that has not been reported in the patent or scientific literature to date.

[00061] Certain embodiments of the presently disclosed and claimed inventive concept(s) also include the use of alternative hosts with the potential for glycosaminoglycan production, including bacteria from both Gram-negative (e.g., *Pseudomonas*, etc.) and Gram-positive classes (e.g., *Bacilli*, *Lactococci*, etc.), as well as other microbes (fungi, archaea, etc). The basic requirements of a recombinant host for use in heparosan production in accordance with the presently disclosed and claimed inventive concept(s) include: (a) the glycosyltransferase(s) that produce heparosan, and (b) the UDP-sugar precursors UDP-GlcNAc and UDP-GlcUA. It should be noted that the latter requirement can be met by either native genes or introduced recombinant genes. The required genes can be either episomally and/or chromosomally located.

[00062] In certain embodiments, the host cell further comprises at least one gene encoding an enzyme for synthesis of a heparosan sugar precursor (i.e., UDP-GlcNAc or UDP-GlcUA). Non-limiting examples of genes encoding an enzyme for synthesis of a heparosan sugar precursor that may be utilized in accordance with the presently disclosed and claimed inventive concept(s) include pyrophosphorylases, transferases, mutases, dehydrogenases, and epimerases.

[00063] The ultra-high MW (= or > 1MDa) heparosan polymer is not known in nature and not been shown or reported by others. As well known in the polymer field, the size distribution affects its physical properties (e.g., viscosity, chain entanglement, solubility). The >1 MDa heparosan described and claimed in the inventive concept(s) is preferred over the naturally occurring heparosan with respect to performance in production of certain biomaterials, such as but not limited to, viscoelastics and hydrogels.

[00064] The presently disclosed and claimed inventive concept(s) is also related to methods of augmenting tissue in a mammalian patient. In such methods, an effective amount of any of the biomaterial compositions described herein above or otherwise contemplated herein is administered to the mammalian patient. The biomaterial composition may be administered to the patient by any method known in the art, including, but not limited to, injection and/or implantation. When injected, the biomaterial composition may be in a liquid state or a suspension of particles, whereas when implanted, the biomaterial composition may be in a gel or semi-solid state, or may be attached to a substrate.

[00065] The presently disclosed and claimed inventive concept(s) also relates to methods of repairing voids in tissues of mammals. In the method, any of the biomaterial compositions described herein above or otherwise contemplated herein is administered into the voids. In certain embodiments, the biomaterial composition may be injected and/or implanted into the voids.

[00066] The presently disclosed and claimed inventive concept(s) also relates to methods of creating voids or viscus in tissues of mammals. In the method, any of the biomaterial compositions described herein above or otherwise contemplated herein are disposed into a tissue or a tissue engineering construct to create the voids or viscus. In certain embodiments, the biomaterial composition may be injected and/or implanted into the tissue/tissue engineering construct to create the voids or viscus.

[00067] The presently disclosed and claimed inventive concept(s) also relates to methods of reparative surgery or plastic surgery. In the method, any of the biomaterial compositions described herein above or otherwise contemplated herein is administered to a patient and serves as a filling material at the site to which it is administered. In certain embodiments, the biomaterial composition may be injected and/or implanted into the patient.

[00068] The presently disclosed and claimed inventive concept(s) further relates to methods of dermal augmentation and/or treatment of skin deficiency in a patient. In the method, any of the biomaterial compositions described herein above or otherwise contemplated herein is administered to the patient. In certain embodiments, the biomaterial composition may be injected and/or implanted into the patient. The biomaterial

composition is biocompatible, swellable, hydrophilic, and substantially non-toxic, and the biomaterial composition swells upon contact with physiological fluids at the administration/injection/implantation site.

[00069] The dermal augmentation method of the presently disclosed and claimed inventive concept(s) is especially suitable for the treatment of skin contour deficiencies, which are often caused by various conditions/exposures, including but not limited to, aging, environmental exposure, weight loss, child bearing, injury, surgery, in addition to diseases such as acne and cancer. Non-limiting examples of contour deficiencies that may be treated in accordance with the presently disclosed and claimed inventive concept(s) include frown lines, worry lines, wrinkles, crow's feet, marionette lines, stretch marks, and internal and external scars resulted from injury, wound, bite, surgery, or accident.

[00070] In addition, the presently disclosed and claimed inventive concept(s) also relates to methods of medical or prophylactic treatment of a mammalian patient. In the method, any of the compositions described herein above or otherwise contemplated herein is administered to the mammalian patient in need of such a treatment. In certain embodiments, the composition may be injected and/or implanted into the mammalian patient.

[00071] Further, the presently disclosed and claimed inventive concept(s) also relates to methods of treatment or prophylaxis of tissue augmentation in a mammalian patient. In the method, a medical or prophylactic composition comprising a polysaccharide gel composition that includes any of the biomaterial compositions described herein above or otherwise contemplated herein is administered to the mammalian patient.

[00072] The presently disclosed and claimed inventive concept(s) is further related to a delivery system for a substance having biological or pharmacological activity. The system comprising a molecular cage formed of a cross-linked gel of heparosan or a mixed cross-linked gel of heparosan and at least one other hydrophilic polymer co-polymerizable therewith. The system further includes a substance having biological or pharmacological activity dispersed therein, wherein the substance is capable of being diffused therefrom in a controlled manner.

[00073] The biomaterials of the presently disclosed and claimed inventive concept(s) may be utilized in any methods of utilizing biomaterials known or otherwise contemplated in the art. For example but not by way of limitation, the biomaterial compositions of the presently disclosed and claimed inventive concept(s) may be utilized in any of the methods of utilizing other known biomaterials that are described in US Patent Nos. 4,582,865, issued to Balazs et al. on April 15, 1986; 4,636,524, issued to Balazs et al. on January 13, 1987; 4,713,448, issued to Balazs et al. on December 15, 1987; 5,137,875, issued to Tsununaga et al. on August 11, 1992; 5,827,937, issued to Ang on October 27, 1998; 6,436,424, issued to Vogel et al. on August 20, 2002; 6,685,963, issued to Taupin et al. on February 3, 2004; and 7,060,287, issued to Hubbard et al. on June 13, 2006;. The entire contents of such patents are hereby expressly incorporated herein by reference, and therefore any of the methods described therein, when utilized with the novel biomaterial compositions of the presently claimed and disclosed inventive concept(s), also fall within the scope of the presently disclosed and claimed inventive concept(s).

[00074] Other specific examples of uses for the biomaterial compositions of the presently disclosed and claimed inventive concept(s) include, but are not limited to: (a) a persistent lubricating coating on a surface, such as, but not limited to, surgical devices; (b) a long lasting moisturizer; (c) a viscoelastic supplement for joint maladies; and (d) a non-thrombotic, non-occluding blood conduit (such as, but not limited to, a stent or artificial vessel, etc.). In addition, any of the biomaterial compositions of the presently disclosed and claimed inventive concept(s) may be utilized in tissue engineering to form a viscus or vessel duct or lumen by using the biomaterial compositions of the presently disclosed and claimed inventive concept(s) as a three-dimensional space maker; in this instance, the surrounding cells will not bind to the biomaterial compositions of the presently disclosed and claimed inventive concept(s), thereby making such biomaterial compositions well suited for this technology.

[00075] In addition, the presently disclosed and claimed inventive concept(s) further includes methods of doing business by producing any of the compositions described or otherwise contemplated herein by the methods described herein above and selling and delivering the compositions to a customer or providing such compositions to a patient.

[00076] In one embodiment of the presently disclosed and claimed inventive concept(s), the compositions of the presently disclosed and claimed inventive concept(s) may be produced using recombinant heparosan synthases as described or otherwise known in the art, including but not limited to, the heparosan synthases disclosed in the inventor's prior patents U.S. Patent Nos. 7,307,159, issued December 11, 2007; 7,771,981, issued May 8, 2002; and 8,088,604, issued January 3, 2012; as well as the heparosan synthases disclosed in the inventor's published patent applications US 2008/0226690, published September 18, 2008; US 2010/0036001, published February 11, 2010; and US 2012/0108802, published May 3, 2012. The entire contents of the above-referenced patents and patent applications, and especially the sequence listings thereof, are expressly incorporated herein by reference as if explicitly disclosed herein.

[00077] Non-limiting examples of heparosan synthases that may be utilized in accordance with the presently disclosed and claimed inventive concept(s) include: a recombinant heparosan synthase having an amino acid sequence as set forth in at least one of SEQ ID NOS: 2, 4, and 6-8; a recombinant heparosan synthase encoded by the nucleotide sequence of at least one of SEQ ID NOS: 1, 3, 5, and 9-11; a recombinant heparosan synthase encoded by a nucleotide sequence capable of hybridizing to a complement of the nucleotide sequence of at least one of SEQ ID NOS: 1, 3, 5, and 9-11 under hybridization conditions comprising hybridization at a temperature of 68°C in 5x SSC/5x Denhardt's solution/1.0% SDS, followed with washing in 3x SSC at 42°C; a recombinant heparosan synthase encoded by a nucleotide sequence capable of hybridizing to a complement of a nucleotide sequence encoding an amino acid sequence as set forth in at least one of SEQ ID NOS: 2, 4, and 6-8 under hybridization conditions comprising hybridization at a temperature of 68°C in 5x SSC/5x Denhardt's solution/1.0% SDS, followed with washing in 3x SSC at 42°C; a recombinant heparosan synthase encoded by a nucleotide sequence capable of hybridizing to a complement of the nucleotide sequence of at least one of SEQ ID NOS: 1, 3, 5, and 9-11 under hybridization conditions comprising hybridization at a temperature of 30°C in 5X SSC, 5X Denhardts reagent, 30% formamide for about 20 hours followed by washing twice in 2X SSC, 0.1% SDS at about 30°C for about 15 min followed by 0.5X SSC, 0.1% SDS at about 30°C for about 30 minutes; and a recombinant heparosan synthase encoded by a nucleotide

sequence capable of hybridizing to a complement of a nucleotide sequence encoding an amino acid sequence as set forth in of at least one of SEQ ID NOS: 2, 4, and 6-8 under hybridization conditions comprising hybridization at a temperature of 30°C in 5X SSC, 5X Denhardt's reagent, 30% formamide for about 20 hours followed by washing twice in 2X SSC, 0.1% SDS at about 30°C for about 15 min followed by 0.5X SSC, 0.1% SDS at about 30°C for about 30 minutes.

[00078] Additional non-limiting examples of heparosan synthases that may be utilized in accordance with the presently disclosed and claimed inventive concept(s) include: a recombinant heparosan synthase that is at least 60% identical to at least one of SEQ ID NOS: 2, 4, and 6-8; a recombinant heparosan synthase that is at least 70% identical to at least one of SEQ ID NOS: 2, 4, and 6-8; a recombinant heparosan synthase that is at least 80% identical to at least one of SEQ ID NOS: 2, 4, and 6-8; a recombinant heparosan synthase that is at least 85% identical to at least one of SEQ ID NOS: 2, 4, and 6-8; a recombinant heparosan synthase that is at least 90% identical to at least one of SEQ ID NOS: 2, 4, and 6-8; a recombinant heparosan synthase that is at least 95% identical to at least one of SEQ ID NOS: 2, 4, and 6-8; a recombinant heparosan synthase encoded by a nucleotide sequence that is at least 60% identical to at least one of SEQ ID NOS: 1, 3, 5, and 9-11; a recombinant heparosan synthase encoded by a nucleotide sequence that is at least 70% identical to at least one of SEQ ID NOS: 1, 3, 5, and 9-11; a recombinant heparosan synthase encoded by a nucleotide sequence that is at least 80% identical to at least one of SEQ ID NOS: 1, 3, 5, and 9-11; a recombinant heparosan synthase encoded by a nucleotide sequence that is at least 85% identical to at least one of SEQ ID NOS: 1, 3, 5, and 9-11; a recombinant heparosan synthase encoded by a nucleotide sequence that is at least 90% identical to at least one of SEQ ID NOS: 1, 3, 5, and 9-11; and a recombinant heparosan synthase encoded by a nucleotide sequence that is at least 95% identical to at least one of SEQ ID NOS: 1, 3, 5, and 9-11.

[00079] The use of truncated heparosan synthase genes to produce any of the compositions described or otherwise contemplated herein also falls within the scope of the presently disclosed and claimed inventive concept(s). For instance, the removal of the last 50 residues or the first 77 residues of PmHS1 (SEQ ID NOS: 7 and 8, respectively) does not

inactivate its catalytic function (Kane et al., 2006). Those of ordinary skill in the art would appreciate that simple amino acid removal from either end of the heparosan synthase sequence can be accomplished. The truncated versions of the sequence simply have to be checked for activity in order to determine if such a truncated sequence is still capable of producing heparosan.

[00080] Similarly, the use of fusion proteins that add other polypeptide segments (to either termini or internally) to the heparosan synthase sequence also falls within the scope of the presently disclosed and claimed inventive concept(s). The fusion protein partner (such as but not limited to, maltose-binding protein, thioredoxin, etc.) can increase stability, increase expression levels in the cell, and/or facilitate the purification process, but the catalytic activity for making the heparosan polymer intrinsic to the inventive concept(s) remains the same.

[00081] The recombinant heparosan synthase utilized in accordance with the presently disclosed and claimed inventive concept(s) also encompass sequences essentially as set forth in SEQ ID NOS:1-8. The term "a sequence essentially as set forth in SEQ ID NO:X" means that the sequence substantially corresponds to a portion of SEQ ID NO:X and has relatively few amino acids or codons encoding amino acids which are not identical to, or a biologically functional equivalent of, the amino acids or codons encoding amino acids of SEQ ID NO:X. The term "biologically functional equivalent" is well understood in the art and is further defined in detail herein, as a gene having a sequence essentially as set forth in SEQ ID NO:X, and that is associated with the ability of prokaryotes to produce HA or a heparosan polymer *in vitro* or *in vivo*. In the above examples, X refers to either SEQ ID NO:1-11 or any additional sequences set forth herein, such as the truncated or mutated versions of pmHS1 that are contained generally in SEQ ID NOS:7-8.

[00082] It is widely recognized that a pair of distinct enzymes with even 30, 50, or 70% identity or similarity at the active site (of functional regions) thereof can possess the same catalytic activity. As most of the protein sequence is a scaffold for the active site, it is not required that all regions of the enzymes be exactly the same between functional enzyme homologs or analogs. In addition, some extra (non-catalytic) sequences may also be

present, thus lowering the total protein similarity levels. Thus, functional regions (and not entire sequences) should be the basis for similarity comparisons between two enzymes.

[00083] These references and countless others indicate that one of ordinary skill in the art, given a nucleic acid sequence or an amino acid sequence, could make substitutions and changes to the nucleic acid/amino acid sequence without changing its functionality (specific examples of such changes are given hereinafter and are generally set forth in SEQ ID NOS:7-8). Also, a substituted nucleic acid segment may be highly identical and retain its enzymatic activity with regard to its unadulterated parent, and yet still fail to hybridize thereto. As such, variations of the sequences that fall within the above-defined functional limitations have been disclosed in the applications incorporated by reference. As such, the presently claimed and disclosed inventive concept(s) should not be regarded as being solely limited to the use of the specific sequences disclosed and/or incorporated by reference herein. Even further, if smaller regions or sequence motifs contain the active site residues or important functional units, this similarity is also indicative of function. The presently disclosed and claimed inventive concept(s) may utilize nucleic acid segments encoding an enzymatically active HS from *P. multocida* - pmHS1 and/or PmHS2. One of ordinary skill in the art would appreciate that substitutions can be made to the pmHS1 or PmHS2 nucleic acid segments listed in SEQ ID NO:1, 3 and 5, respectively, without deviating outside the scope and claims of the presently disclosed and claimed inventive concept(s). Standardized and accepted functionally equivalent amino acid substitutions are presented in Table 1. In addition, other analogous or homologous enzymes that are functionally equivalent to the disclosed synthase sequences would also be appreciated by those skilled in the art to be similarly useful in the methods of the presently disclosed and claimed inventive concept(s), that is, a new method to control precisely the size distribution of the heparosan polymer.

TABLE 1

Amino Acid Group	Conservative and Semi-Conservative Substitutions
NonPolar R Groups	Alanine, Valine, Leucine, Isoleucine, Proline, Methionine, Phenylalanine, Tryptophan
Polar, but uncharged, R Groups	Glycine, Serine, Threonine, Cysteine, Asparagine, Glutamine
Negatively Charged R Groups	Aspartic Acid, Glutamic Acid
Positively Charged R Groups	Lysine, Arginine, Histidine

[00084] Therefore, the presently disclosed and claimed inventive concept(s) also includes the use of heparosan synthases that have amino acid sequences that differ from at least one of SEQ ID NOS:2, 4, and 6-8 by at least one of the following: the presence of 1-60 amino acid additions, deletions, or substitutions when compared to at least one of SEQ ID NOS:2, 4, and 6-8; the presence of 1-55 amino acid additions, deletions, or substitutions when compared to at least one of SEQ ID NOS:2, 4, and 6-8; the presence of 1-50 amino acid additions, deletions, or substitutions when compared to at least one of SEQ ID NOS:2, 4, and 6-8; the presence of 1-45 amino acid additions, deletions, or substitutions when compared to at least one of SEQ ID NOS:2, 4, and 6-8; the presence of 1-40 amino acid additions, deletions, or substitutions when compared to at least one of SEQ ID NOS:2, 4, and 6-8; the presence of 1-35 amino acid additions, deletions, or substitutions when compared to at least one of SEQ ID NOS:2, 4, and 6-8; the presence of 1-30 amino acid additions, deletions, or substitutions when compared to at least one of SEQ ID NOS:2, 4, and 6-8; the presence of 1-25 amino acid additions, deletions, or substitutions when compared to at least one of SEQ ID NOS:2, 4, and 6-8; the presence of 1-20 amino acid additions, deletions, or substitutions when compared to at least one of SEQ ID NOS:2, 4, and 6-8; the presence of 1-15 amino acid additions, deletions, or substitutions when compared to at least one of SEQ ID NOS:2, 4, and 6-8; the presence of 1-10 amino acid additions, deletions, or substitutions when compared to at least one of SEQ ID NOS:2, 4, and 6-8; and the presence of 1-5 amino acid additions, deletions, or substitutions when compared to at least one of SEQ ID NOS:2, 4, and 6-8.

[00085] Allowing for the degeneracy of the genetic code as well as conserved and semi-conserved substitutions, sequences which have between about 40% and about 99%; or more preferably, between about 60% and about 99%; or more preferably, between about 70% and about 99%; or more preferably, between about 80% and about 99%; or even more preferably, between about 90% and about 99% *identity* to the nucleotides of at least one of SEQ ID NO: 1, 3, 5, and 9-11 will be sequences which are "essentially as set forth" in at least one of SEQ ID NO: 1, 3, 5 and 9-11. Sequences which are essentially the same as those set forth in at least one of SEQ ID NO: 1, 3, 5 and 9-11 may also be functionally defined as sequences which are capable of hybridizing to a nucleic acid segment containing the complement of at least one of SEQ ID NO: 1, 3, 5, and 9-11 under standard stringent hybridization conditions, "moderately stringent hybridization conditions," "less stringent hybridization conditions," or "low stringency hybridization conditions." Suitable standard or less stringent hybridization conditions will be well known to those of skill in the art and are clearly set forth hereinbelow. In a preferred embodiment, standard stringent hybridization conditions or less stringent hybridization conditions are utilized.

[00086] The terms "standard stringent hybridization conditions," "moderately stringent conditions," and less stringent hybridization conditions or "low stringency hybridization conditions" are used herein, describe those conditions under which substantially complementary nucleic acid segments will form standard Watson-Crick base-pairing and thus "hybridize" to one another. A number of factors are known that determine the specificity of binding or hybridization, such as pH; temperature; salt concentration; the presence of agents, such as formamide and dimethyl sulfoxide; the length of the segments that are hybridizing; and the like. There are various protocols for standard hybridization experiments. Depending on the relative similarity of the target DNA and the probe or query DNA, then the hybridization is performed under stringent, moderate, or under low or less stringent conditions.

[00087] The hybridizing portion of the hybridizing nucleic acids is typically at least about 14 nucleotides in length, and preferably between about 14 and about 100 nucleotides in length. The hybridizing portion of the hybridizing nucleic acid is at least about 60%, e.g., at least about 80% or at least about 90%, identical to a portion or all of a nucleic acid sequence

encoding a heparin/heparosan synthase or its complement, such as SEQ ID NO:1, 3, 5, 9, 10, or 11, or the complement thereof. Hybridization of the oligonucleotide probe to a nucleic acid sample typically is performed under standard or stringent hybridization conditions. Nucleic acid duplex or hybrid stability is expressed as the melting temperature or T_m , which is the temperature at which a probe nucleic acid sequence dissociates from a target DNA. This melting temperature is used to define the required stringency conditions. If sequences are to be identified that are related and substantially identical to the probe, rather than identical, then it is useful to first establish the lowest temperature at which only homologous hybridization occurs with a particular concentration of salt (e.g., Standard Saline Citrate (SSC), Saline Sodium Phosphate EDTA (SSPE), or High Phosphate Buffer (HPB) solutions). Then, assuming that 1% mismatching results in a 1°C decrease in the T_m , the temperature of the final wash in the hybridization reaction is reduced accordingly (for example, if sequences having >95% identity with the probe are sought, the final wash temperature is decreased by about 5°C). In practice, the change in T_m can be between about 0.5°C and about 1.5°C per 1% mismatch. Examples of standard stringent hybridization conditions include hybridizing at about 68°C in 5x SSC/5x Denhardt's solution/1.0% SDS, followed with washing in 0.2x SSC/0.1% SDS at room temperature or hybridizing in 1.8x HPB at about 30°C to about 45°C followed by washing a 0.2-0.5xHPB at about 45°C. Moderately stringent conditions include hybridizing as described above in 5xSSC\5xDenhardt's solution 1% SDS washing in 3x SSC at 42°C. The parameters of salt concentration and temperature can be varied to achieve the optimal level of identity between the probe and the target nucleic acid. Additional guidance regarding such conditions is readily available in the art, for example, by Sambrook et al., 1989, *Molecular Cloning, A Laboratory Manual*, (Cold Spring Harbor Press, N.Y.); and Ausubel et al. (eds.), 1995, *Current Protocols in Molecular Biology*, (John Wiley & Sons, N.Y.). Several examples of low stringency protocols include: (A) hybridizing in 5X SSC, 5X Denhardts reagent, 30% formamide at about 30°C for about 20 hours followed by washing twice in 2X SSC, 0.1% SDS at about 30°C for about 15 min followed by 0.5X SSC, 0.1% SDS at about 30°C for about 30 min (FEMS Microbiology Letters, 2000, vol. 193, p. 99-103); (B) hybridizing in 5X SSC at about 45°C overnight followed by washing with 2X SSC, then by 0.7X SSC at about 55°C (J. Viological Methods, 1990, vol. 30, p.

141-150); or (C) hybridizing in 1.8XHPB at about 30°C to about 45°C; followed by washing in 1X HPB at 23°C.

[00088] The DNA segments that may be utilized to produce the compositions of the presently disclosed and claimed inventive concept(s) encompass DNA segments encoding biologically functional equivalent HS proteins and peptides. Such sequences may arise as a consequence of codon redundancy and functional equivalency which are known to occur naturally within nucleic acid sequences and the proteins thus encoded. Alternatively, functionally equivalent proteins or peptides may be created via the application of recombinant DNA technology, in which changes in the protein structure may be engineered, based on considerations of the properties of the amino acids being exchanged. Changes designed by man may be introduced through the application of site-directed mutagenesis techniques, e.g., to introduce improvements to the enzyme activity or to antigenicity of the HS protein or to test HS mutants in order to examine HS activity at the molecular level or to produce HS mutants having changed or novel enzymatic activity and/or sugar substrate specificity.

[00089] The presently disclosed and claimed inventive concept(s) also include the use of nucleotide sequences encoding any of the heparosan synthases described or otherwise contemplated herein, wherein the nucleotide sequences are synthetic sequences that have been gene-optimized for expression in a particular host cell. Specific, non-limiting examples of gene-optimized heparosan synthase encoding nucleotide sequences are provided in SEQ ID NOS:9-11. SEQ ID NOS:9-10 include nucleotide sequences encoding the heparosan synthase of SEQ ID NO:2 and which have been gene-optimized for expression in *E. coli*. SEQ ID NO:11 includes a nucleotide sequence encoding the heparosan synthase of SEQ ID NO:2 and which have been gene-optimized for expression in *Bacillus*.

[00090] However, the scope of the inventive concept(s) is not limited to these particular sequences, but rather includes gene-optimized nucleotide sequences that encode any heparosan synthase described or otherwise contemplated herein (such as, but not limited to heparosan synthase amino acid sequences that are a certain percentage identical to at least one of SEQ ID NOS:2, 4, and 6-8, as well as heparosan synthase amino acid sequences that

contain one or more additions, deletions, or substitutions when compared to at least one of SEQ ID NOS:2, 4, and 6-8).

[00091] The use of gene-optimized sequences is known and used in the art to increase expression of the gene sequence within the heterologous host. However, a novel product was unexpectedly produced from the heparosan synthase expressed in *E. coli* when the *Pasteurella* gene sequence was gene-optimized and expressed in *E. coli*. The inventive concept(s) disclose the production of mega-Dalton molecular weight heparosan polymers, and this novel species has never before been reported in any known microbes. One of ordinary skill in the art would assume that optimization of a gene sequence encoding an enzyme would result in increased expression of that enzyme in the heterologous host, thereby resulting in increased production of the same enzyme-derived product (i.e., higher amounts of the heparosan polymer of the typical size found in the native microbes) produced in the native host. Unexpectedly, the expression of gene-optimized *Pasteurella multocida* heparosan synthase in *E. coli* resulted in a new species of product – an ultra-high molecular weight heparosan polymer. Production of heparosan polymers of this size have not been reported for any other microbe. In addition, the heparosan polymers produced in accordance with the presently disclosed and claimed inventive concept(s) exhibit superior and advantageous properties compared to the lower molecular weight products currently known in the art. These properties provide enhanced utility for the heparosan polymer in the biomaterials field. For example, but not by way of limitation, the ultra-high molecular weight (MW) heparosan polymers produced in accordance with the presently disclosed and claimed inventive concept(s) exhibit enhanced solution viscosity and can be used at lower concentrations (either with or without chemical crosslinking) than the naturally occurring heparosan preparations.

[00092] The presently disclosed and claimed inventive concept(s) further includes isolated nucleotide sequences, along with recombinant host cells containing same, that contain any of the gene-optimized heparosan synthase sequences disclosed or otherwise contemplated herein.

[00093] Heparosan, a sugar polymer that is the natural biosynthetic precursor of heparin and heparan sulfate, has numerous characteristics that indicate that this material exhibits

enhanced performance in a variety of medical applications or medical devices. In comparison to HA and heparin, two very structurally similar polymers used in many current applications in several large markets, heparosan is more stable in the body, as no naturally occurring enzymes degrade heparosan, and therefore the biomaterial compositions of the presently disclosed and claimed inventive concept(s) should have longer lifetimes compared to presently used biomaterials. In addition, heparosan interacts with fewer proteins (thus less fouling) and cells (thus less infiltration, scarring, or clotting) when compared to existing biomaterials.

[00094] The heparosan chain does not contain sulfate groups; thus, the degrading enzyme heparanase, the anticoagulation system proteins of blood, the cell surface binding receptors, and growth factors and cytokines will not specifically bind the polymer. This characteristic leads to an inert character in the body, thereby providing long half-life in the extracellular space in addition to not stimulating or inducing cellular behaviors (e.g., growth, migration, binding, activation, etc). However, once in the cell, the heparosan chain can be degraded by normal metabolic systems such as the exoglycosidases in the lysosomes.

[00095] In comparison to synthetic plastics or carbon, the natural hydrophilicity (aka water-loving) characteristics of heparosan also enhance tissue compatibility. Animal-derived proteins (e.g., collagen, bovine serum albumin) and calcium hydroxyapatite often have side effects, including but not limited to, eliciting an allergic response and/or stimulating granulation (5). On the other hand, even certain pathogenic bacteria use heparosan to hide in the body since this polymer is non-immunogenic (8-10). The biomaterial compositions of the presently disclosed and claimed inventive concept(s) produced from a non-animal source also promise to be free of adventitious agents (e.g., vertebrate viruses, prions) that could potentially contaminate animal- or human-derived sources.

[00096] Certain carbohydrates play roles in forming and maintaining the structures of multicellular organisms in addition to more familiar roles as nutrients for energy. Glycosaminoglycans [GAGs], long linear polysaccharides consisting of disaccharide repeats that contain an amino sugar, are well known to be essential in vertebrates (9, 11-15). The GAG structures possess many negative groups and are replete with hydroxyl groups,

therefore these sugars have a high capacity to adsorb water and ions. Heparin/heparan (backbone $[\beta 4\text{GlcUA}-\alpha 4\text{GlcNAc}]_n$), chondroitin (backbone $[\beta 4\text{GlcUA}-\beta 3\text{GalNAc}]_n$), and hyaluronan (HA; backbone $[\beta 4\text{GlcUA}-\beta 3\text{GlcNAc}]_n$) are the three most prevalent GAGs in humans. Depending on the tissue and cell type, the GAGs are structural, adhesion, and/or signaling elements. A few clever microbes also produce extracellular polysaccharide coatings, called capsules, composed of GAG chains that serve as virulence factors (9, 10). The capsule is thought to assist in the evasion of host defenses such as phagocytosis and complement. As the microbial polysaccharide is identical or very similar to the host GAG, the antibody response is either very limited or non-existent.

[00097] In humans, heparosan only exists transiently, serving as a precursor to the more highly modified final products of heparan sulfate and heparin. In contrast, the bacterial strains set forth herein produce heparosan as their final product (16). Due to the less complex makeup of bacterial cells and to the relative ease with which their growth and expression can be modulated, harvesting a polymer from microbes is much easier, more scalable, and less expensive than extracting from animal tissues. In addition, the polymer in the currently described inventive concept(s), namely the ultra high MW (1 to 6.8 MDa) heparosan derived from our recombinant system has not previously existed or been reported in nature.

[00098] Dermal fillers serve as soft tissue replacements or augmentation agents (5, 6). The need for a dermal filler may arise from aging (loss of HA and elastin), trauma (loss of tissue), acne (severe pitting), and/or atrophy (certain wasting diseases including lipatrophy). Three important characteristics that dermal fillers must possess include *a*) space-filling ability, *b*) maintenance of hydration, and *c*) biocompatibility (5). Currently, polysaccharides, proteins, plastics, and ceramics have been used as biomaterials in dermal fillers. With respect to aesthetic appearance and ease of implantation, softer injectable gels have better attributes; thus, polysaccharides and proteins are widely used. In addition to therapeutic uses, cosmetic applications are becoming more widespread. Alternatives to dermal filler treatment are the use of *(i)* plastic surgery (tightening the skin), *(ii)* nerve killing agents such as BOTOX® (relax muscles), and *(iii)* the use of autologous fat. Compared to dermal fillers, these alternatives are more invasive and/or leave the patient with an

unnatural appearance (5, 6). For victims of trauma, scarring, or severe disease, an aim of the therapy is to instill more self-confidence and better disposition; this effect should not be discounted, as a patient's state of mind is important for overall healing.

[00099] A major goal of bioengineering is the design of implanted artificial devices to repair or to monitor the human body. High-strength polymers, durable alloys, and versatile semiconductors have many properties that make these materials desirable for bioengineering tasks. However, the human body has a wide range of defenses and responses that evolved to prevent infections and to remove foreign matter that hinders the utilization of modern man-made substances (17, 18). Improving the biocompatibility of these materials will remove a significant bottleneck in the advancement of bioengineering.

[000100] A leading example of a medical need for improved surface coatings lies in cardiovascular disease. Damage from this disease is a very prevalent and expensive problem; the patient's system is oxygen- and nutrient-starved due to poor blood flow. The availability of blood vessel grafts from transplants (either autologous or donor) is limited as well as expensive. Therefore, the ability to craft new artificial vessels is a goal, but will take more time to perfect due to the complex engineering and biological requirements. Another current, more approachable therapeutic intervention employs stents, artificial devices that prop open the inner cavity of a patient's blood vessel. As summated by Jordan & Chaikof, "The development of a clinically durable small-diameter vascular graft as well as permanently implantable biosensors and artificial organ systems that interface with blood, including the artificial heart, kidney, liver, and lung, remain limited by surface-induced thrombotic responses" (7). Thus, to advance this technology further, thromboresistant surface coatings are needed that inhibit: (i) protein and cell adsorption, (ii) thrombin and fibrin formation, and (iii) platelet activation and aggregation.

[000101] Artificial plastics (poly[lactide] in SCULPTRA® (Sanofi-Aventis) or poly[methylmethacrylate] in ARTECOLL® (Artes Medical, Inc., San Diego, CA), ceramics (calcium hydroxyapatite in RADIESSE® (Bioform Medical, Inc., San Mateo, CA)) or pure carbon have utility for many therapeutic applications (1,5,7,18), but in many respects, their chemical and physical properties are not as optimal as polysaccharides for the targeted goals of dermal fillers or surface coatings. The most critical issues are lack of good

wettability (due to poor interaction with water) and/or hardness (leading to an unnatural feel or brittleness). The presently claimed and disclosed inventive concept(s) is related to the use of heparosan to replace and supplant useful sugar polymers that are hydrophilic (water loving) and may be prepared in a soft form.

[000102] In addition to HA and heparin, other polysaccharides such as dextran ($[\alpha 6\text{Glc}]_n$), cellulose ($[\beta 4\text{Glc}]_n$), or chitosan ($[\beta 4\text{GlcN}]_n$) have many useful properties, but since they are not naturally anionic (negatively charged), these polymers do not mimic the natural extracellular matrix or blood vessel surfaces. Cellulose and dextran can be chemically transformed into charged polymers that help increase their biocompatibility and improve their general physicochemical properties, but harsh conditions are required leading to batch-to-batch variability and quality issues. On the other hand, GAGs, the natural polymers, have intrinsic negative charges.

[000103] HA and heparin have been employed as biomaterial coatings for vascular prosthesis and stents (artificial blood vessels and supports), as well as coatings on intraocular lenses and soft-tissue prostheses (7, 22). The rationale is to prevent blood clotting, enhance fouling resistance, and prevent post-surgery adhesion (when organs stick together in an undesirable fashion). The biomaterial compositions of the presently disclosed and claimed inventive concept(s) should also be suitable as a coating, as described in greater detail herein after.

[000104] A key advantage with heparosan is that it has increased biostability in the extracellular matrix when compared to other GAGs. As with most compounds synthesized in the body, new molecules are made, and after serving their purpose, are broken down into smaller constituents for recycling. Heparin and heparan sulfate are eventually degraded and turned over by a single enzyme known as heparanase (23, 24). Experimental challenge of heparosan and N-sulfo-heparosan with heparanase, however, shows that these polymers lacking O-sulfation are not sensitive to enzyme action *in vitro* (25, 26). These findings demonstrate that heparosan is not fragmented enzymatically in the body. Overall, this indicates that heparosan is a very stable biomaterial.

EXAMPLES

[000105] Examples are provided hereinbelow. However, the present invention is to be understood to not be limited in its application to the specific experimentation, results and laboratory procedures. Rather, the Examples are simply provided as one of various embodiments and are meant to be exemplary, not exhaustive.

EXAMPLE 1

[000106] Gene-optimized pmHS1 sequences for expression in *E. coli* and *Bacillus*. Three gene-optimized sequences encoding the *Pasteurella multocida* heparosan synthase of SEQ ID NO:2 were obtained. Two of the sequences (SEQ ID NOS:9 and 10) were gene-optimized for expression in *E. coli*, while the third sequence (SEQ ID NO:11) was gene-optimized for expression in *Bacillus*.

[000107] Figure 1A contains an alignment of the two *E. coli* gene-optimized sequences, SEQ ID NOS:9 and 10, with the native *Pasteurella multocida* heparosan synthase gene (SEQ ID NO:1). Figure 1B contains an alignment of only the two *E. coli* gene-optimized sequences, SEQ ID NOS:9 and 10. Figure 1C contains an alignment of the *Bacillus* gene-optimized sequence (SEQ ID NO:11) with the native *Pasteurella multocida* heparosan synthase gene (SEQ ID NO:1).

[000108] Table 2 illustrates the percent identity between the two gene-optimized sequences of SEQ ID NOS:9-10 and the native *Pasteurella multocida* gene sequence (SEQ ID NO:1). Note that all three sequences encode amino acid sequences that are 100% identical to the amino acid sequence of SEQ ID NO:2. As can be seen, the two gene-optimized sequences are approximately 74% identical to the native *Pasteurella* gene sequence. It is also noted that the two gene-optimized sequences are only 95% identical to each other, so there is some variation obtained from the algorithm that is being used to generate the optimized sequence.

TABLE 2: Percent Identities of Gene-optimized and Native Heparosan Synthase Gene Sequences

	pmHS1 (SEQ ID NO:1)	pmHS1-opt1 (SEQ ID NO:9)	pmHS1-opt2 (SEQ ID NO:10)
pmHS1 (SEQ ID NO:1)		74.3%	73.7%
pmHS1-opt1 (SEQ ID NO:9)	74.3%		94.5%

pmHS1-opt2 (SEQ ID NO:10)	73.7%	94.5%	
------------------------------	-------	-------	--

EXAMPLE 2

[000109] Production of High MW Heparosan Polysaccharide. There are two types of naturally occurring microbes, (a) certain *Pasteurella multocida* bacteria (Type D) and their related brethren such as certain *Avibacteria*, and (b) *Escherichia coli* K5 and their related brethren that make an extracellular coating composed of unsulfated heparosan polymer that is readily harvested from the culture media. An unexpected and advantageous characteristic has been discovered for the recombinant (gene-optimized *Pasteurella* gene in an *E. coli* host) heparosan over both natural bacterial heparosan and mammalian heparin; the heparosan produced in accordance with the presently disclosed and claimed inventive concept(s) has a higher molecular weight of approximately 1 to 6.8 MDa (1,000 to 6,800 kDa); therefore, gels or liquid viscoelastics formed of this recombinant heparosan should be easier to produce.

[000110] Transformation of gene-optimized pmHS1 into *E. coli*: Synthetic pmHS1 gene-optimized nucleotide sequence (SEQ ID NO:9) was obtained from GenScript USA Inc. (Piscataway, NJ) and ligated into a pKK223-3 plasmid. The plasmid containing the pmHS1 gene was then transformed into chemically competent *E. coli* K5 cells.

[000111] Heparosan Production and Testing: *E. coli* K5 cells expressing the gene-optimized pmHS1 gene were grown in synthetic media at 30°C in a 14 L fermentor for approximately 40 hours. Spent culture medium (the liquid part of culture after microbial cells are removed) was harvested (by centrifugation at 10,000 x g for 60 minutes), and aliquots thereof were analyzed by agarose gel electrophoresis (1X TAE buffer, 0.8-1.5% agarose) followed by visualization with Stains-All (Lee & Cowman, Anal. Biochem., 1994). The heparosan polymer size was determined by comparison to monodisperse HA size standards (HiLadder, Hyalose, LLC).

[000112] The yield of the heparosan in the spent media was checked by carbazole assays for uronic acid. The carbazole assay is a spectrophotometric chemical assay that measures the amount of uronic acid in the sample via production of a pink color; every other sugar in

the heparosan chain is a glucuronic acid. The detection limit of the carbazole assay is approximately 5 micrograms of polymer.

[000113] The identity of the polymer as heparosan was tested by heparin lyase III (*Pedobacter*) digestion; any heparin-like polysaccharide will be cleaved into small fragments (oligosaccharides) that run at the dye front on an agarose gel and do not stain well with Stains-All.

[000114] Various advantages of the presently disclosed and claimed inventive concept(s) are outlined in Tables 3 and 4.

Table 3:
Comparison of Heparosan and Existing Surgical Biomaterials for Coating Applications

Key Variable	Project Target	Current Practice	Associated Barrier of Current Procedure	Innovative Approaches of Inventive Concept(s)
Coating Stability	Long lasting (weeks-months).	HA, heparin, Bovine serum albumin (BSA) Carbon (C) Lipids (L)	Degraded by body's natural enzymes --- Shed from surface	Use heparosan, a polymer that is not enzymatically digested in human body.
Wettability	Freely interacts with water.	BSA, HA, heparin, L C	--- Hydrophobic	Use water-loving heparosan polymer.
Fouling, Clotting	Surface does not bind proteins or cells.	HA, heparin BSA, C,L	Blood cells & clotting factors bind ---	Use relatively biologically inert heparosan polymer.
Disease Transmission	Zero risk of animal virus or prions.	HA [chicken], CG HA [bacterial], PP, CHP	Potential risk ---	Use non-animal, bacterially derived heparosan.

Table 4:
Comparison of Heparosan and Existing Biomaterials for Surface Coating Applications

Key Variable	Project Target	Current Practice	Associated Barrier of Current Procedure	Innovative Approaches of Inventive Concept(s)
Semi-stable Gel Formation	Injectable, Soft, long-lasting (>12-24 months), but <u>not</u> permanent gel.	Hyaluronan Gel (HA) Collagen Gel (CG) Plastic Particles (PP) Ca Hydroxyapatite Particles (CHP)	Too short lifetime Grainy appearance & too long lifetime Grainy appearance too long lifetime, & cannot inject easily	Use heparosan, a polymer that is <u>not</u> enzymatically digested in human body, and is <u>not</u> a coarse, hard material.
Immunogenicity, Allergenicity	No antibody generation.	HA [bacterial], PP, CHP HA [chicken], CG [bovine>human]	--- Immune or allergic response	Use heparosan polymer that looks 'human' and does not trigger immune system.
Infiltration	Reduce cell adhesion and/or signaling.	HA PP, CHP CG	Proteins & cells bind --- Cells bind	Use heparosan polymer that lacks known adhesion domains or chemotactic signals.
Disease Transmission	Zero risk of human or animal virus and/or prions.	HA [chicken], CG HA [bacterial], PP, CHP	Potential risk ---	Use non-animal, bacterially derived heparosan.
X-ray Imaging Compatible	No opaque or marked areas.	HA, CG PP, CHP	--- Obscures images	Use X-ray-transparent heparosan.
Abundant Resource	Renewable & not overly expensive to produce.	CG [human] HA, CHP, PP, CHP	Limited tissue bank supply or cell culture derived (costly) ---	Use heparosan made via bacterial fermentation.

EXAMPLE 3

[000115] **Production of mega-Dalton molecular weight heparosan.** Agarose gel analysis of ultra-high molecular weight heparosan polymer produced according to the method of Example 2 was performed. The agarose gel analysis (1X TAE, Stains-All detection) shown in Figure 2 demonstrated that the construct of the plasmid-borne recombinant *PmHS1* gene from *P. multocida* Type D in *E. coli* K5 (**Ec K5 + pmHS1**) produced a very high MW heparosan polymer (~1 to ~4.5 MDa; band marked with a *bracket*). As a negative control, the same *E. coli* host with vector alone (**Ec K5 + vector**) only produced a low MW polymer (~50 kDa to ~100 kDa; marked with an *arrow*). **Std** = SelectHA MegaLadder/SelectHA HiLadder/Select HA LoLadder (Hyalose LLC) with bands from top to bottom: 6100, 4570, 3050, 1510, 1090, 966, 572, 495, 310, 214, 110, 27 kDa (kDa = 1,000 Da; MDa = 1,000 kDa). Plasmids: **Vector** = (pKK223-3); **PmHS1** = (pKK223-3/PmHS1).

EXAMPLE 4

[000116] **Production of mega-Dalton molecular weight heparosan in *E. coli* BL21(DE3).** *E. coli* BL21(DE3) [NEB], an *E. coli* strain with distinct genetics from K5 and K12 strains, was transformed with either pKK223-3/gene-optimized PmHS1 (**P**) or pMAL-C4e/gene-optimized PmHS1 (**M**), an expression plasmid producing a maltose-binding protein (MBP)-PmHS1 fusion protein. Cultures of the transformants were induced with IPTG and then grown overnight in either LB (**LB**) or a synthetic media (**Syn**). The culture media was then clarified by centrifugation and the heparosan polymer concentrated by ethanol precipitation. The identity of the heparosan polymer was confirmed by digestion with heparin lyase III (**+LYASE**). The agarose gel analysis (1X TAE, Stains-All detection) shown in Figure 3 demonstrated that the construct of the plasmid-borne recombinant *PmHS1* gene from *P. multocida* Type D in *E. coli* BL21(DE3) produced a very high MW heparosan polymer (~2 to 6.8 MDa; extent of the high MW band marked with a *bracket*). **Mega** = SelectHA MegaLadder (Hyalose LLC) with bands from top to bottom: 6100, 4570, 3050, 1510 kDa, **Std** = SelectHA HiLadder/SelectHA LoLadder (Hyalose LLC) with bands from top to bottom: 1510, 1090, 966, 572, 495, 310, 214, 110, 27 kDa (kDa = 1,000 Da; MDa = 1,000 kDa).

EXAMPLE 5

[000117] Production of mega-Dalton molecular weight heparosan in *E. coli* BL21 Express I^q *E. coli* BL21Express I^q (NEB) was transformed with pMAL-C4e/gene-optimized PmHS1, an expression plasmid producing an MBP-PmHS1 fusion protein. Cultures of the transformants were induced with IPTG and then grown overnight in synthetic media. The culture media was then clarified by centrifugation, and the heparosan polymer concentrated by ethanol precipitation. The identity of the heparosan polymer was confirmed by digestion of the polymer (**START**) with heparin lyase III (**+LYASE**). The agarose gel analysis (1X TAE, Stains-All detection) shown in Figure 4 demonstrated that the construct of the plasmid-borne recombinant, gene-optimized *PmHS1* gene (encoding PmHS from *P. multocida* Type D) in *E. coli* BL21 Express I^q produced a very high MW heparosan polymer (~2 to 6.8 MDa; band marked with a *bracket*). **Mega** = SelectHA MegaLadder (Hyalose LLC) with bands from top to bottom: 6100, 4570, 3050, 1510 kDa.

EXAMPLE 6

[000118] Effect of deletion of heparosan production in *E. coli* K5 on production of mega-Dalton molecular weight heparosan The *kfiA*, *kfiB*, and *kfiC* genes in *E. coli* K5 were deleted, and the resulting strain (**K5-**) no longer produces the 50-80 kDa heparosan usually produced by K5. The K5- strain was transformed with either pKK223-3/gene-optimized PmHS1 (**P**) or pMAL-C4e/gene-optimized PmHS1 (**M**). Cultures of the transformants were induced with IPTG and then grown overnight in either LB. The culture media was then clarified by centrifugation, and the heparosan polymer concentrated by ethanol precipitation. The identity of the heparosan polymer was confirmed by digestion with heparin lyase III (**+LYASE**). The agarose gel analysis (1X TAE, Stains-All detection) shown in Figure 5 demonstrated that the construct of the plasmid-borne recombinant gene-optimized *PmHS1* gene from *P. multocida* Type D, expressed in *E. coli* K5 with no *kfiA*, *kfiB*, or *kfiC* genes, produced a very high MW heparosan polymer (~2 MDa; band marked with a *bracket*). **Std** = SelectHA MegaLadder/SelectHA HiLadder/SelectHA LoLadder (Hyalose LLC) with bands from top to bottom: 6100, 4570, 3050, 1510, 1090, 966, 572, 495, 310, 214, 110, 27 kDa (kDa = 1,000 Da; MDa = 1,000 kDa).

[000119] Thus, the *kfiA*, *kfiB*, and *kfiC* genes are not involved in the production of ultra-high MW heparosan in *E. coli* K5.

[000120] Although the foregoing inventive concept(s) has been described in detail by way of illustration and example for purposes of clarity of understanding, it will be obvious to those skilled in the art that certain changes and modifications may be practiced without departing from the spirit and scope thereof, as described in this specification and as defined in the appended claims below.

REFERENCES

The following references, to the extent that they provide exemplary procedural or other details supplementary to those set forth herein, are specifically incorporated herein by reference in their entirety as though set forth herein particular.

1. Burg, K. J., Porter, S., and Kellam, J. F. (2000) Biomaterial developments for bone tissue engineering *Biomaterials* **21**, 2347-2359
2. Luo, Y., Kirker, K. R., and Prestwich, G. D. (2000) Cross-linked hyaluronic acid hydrogel films: new biomaterials for drug delivery *J Control Release* **69**, 169-184
3. Morra, M. (2005) Engineering of biomaterials surfaces by hyaluronan *Biomacromolecules* **6**, 1205-1223
4. Olivier, V., Faucheux, N., and Hardouin, P. (2004) Biomaterial challenges and approaches to stem cell use in bone reconstructive surgery *Drug Discov Today* **9**, 803-811
5. Johl, S. S., and Burgett, R. A. (2006) Dermal filler agents: a practical review *Curr Opin Ophthalmol* **17**, 471-479
6. Eppley, B. L., and Dadvand, B. (2006) Injectable soft-tissue fillers: clinical overview *Plast Reconstr Surg* **118**, 98e-106e
7. Jordan, S. W., and Chaikof, E. L. (2007) Novel thromboresistant materials *J Vasc Surg* **45 Suppl A**, A104-115
8. DeAngelis, P. L. (2002) Microbial glycosaminoglycan glycosyltransferases *Glycobiology* **12**, 9R-16R
9. DeAngelis, P. L. (2002) Evolution of glycosaminoglycans and their glycosyltransferases: Implications for the extracellular matrices of animals and the capsules of pathogenic bacteria *Anatomical Record* **268**, 317-326
10. Jann, K., and Jann, B. (1992) Capsules of *Escherichia coli*, expression and biological significance *Can J Microbiol* **38**, 705-710
11. Sugahara, K., and Kitagawa, H. (2002) Heparin and heparan sulfate biosynthesis *IUBMB Life* **54**, 163-175
12. Esko, J. D., and Lindahl, U. (2001) Molecular diversity of heparan sulfate *J Clin Invest* **108**, 169-173

13. Hardingham, T. E., and Fosang, A. J. (1992) Proteoglycans: many forms and many functions *Faseb J* **6**, 861-870
14. Laurent, T. C., and Fraser, J. R. (1992) Hyaluronan *Faseb J* **6**, 2397-2404
15. Toole, B. P. (2000) Hyaluronan is not just a goo! *J Clin Invest* **106**, 335-336
16. DeAngelis, P. L., Gunay, N. S., Toida, T., Mao, W. J., and Linhardt, R. J. (2002) Identification of the capsular polysaccharides of Type D and F *Pasteurella multocida* as unmodified heparin and chondroitin, respectively *Carbohydr Res* **337**, 1547-1552
17. Gorbet, M. B., and Sefton, M. V. (2004) Biomaterial-associated thrombosis: roles of coagulation factors, complement, platelets and leukocytes *Biomaterials* **25**, 5681-5703
18. Ma, Z., Mao, Z., and Gao, C. (2007) Surface modification and property analysis of biomedical polymers used for tissue engineering *Colloids Surf B Biointerfaces*
19. Massia, S. P., Holecko, M. M., and Ehteshami, G. R. (2004) In vitro assessment of bioactive coatings for neural implant applications *J Biomed Mater Res A* **68**, 177-186
20. Czaja, W. K., Young, D. J., Kawecki, M., and Brown, R. M., Jr. (2007) The future prospects of microbial cellulose in biomedical applications *Biomacromolecules* **8**, 1-12
21. Chandy, T., and Sharma, C. P. (1990) Chitosan--as a biomaterial *Biomater Artif Cells Artif Organs* **18**, 1-24
22. Allison, D. D., and Grande-Allen, K. J. (2006) Review. Hyaluronan: a powerful tissue engineering tool *Tissue Eng* **12**, 2131-2140
23. McKenzie, E., Young, K., Hircock, M., Bennett, J., Bhaman, M., Felix, R., Turner, P., Stamps, A., McMillan, D., Saville, G., Ng, S., Mason, S., Snell, D., Schofield, D., Gong, H., Townsend, R., Gallagher, J., Page, M., Parekh, R., and Stubberfield, C. (2003) Biochemical characterization of the active heterodimer form of human heparanase (Hpa1) protein expressed in insect cells *Biochem J* **373**, 423-435
24. Vlodavsky, I., Friedmann, Y., Elkin, M., Aingorn, H., Atzmon, R., Ishai-Michaeli, R., Bitan, M., Pappo, O., Peretz, T., Michal, I., Spector, L., and Pecker, I. (1999) Mammalian heparanase: gene cloning, expression and function in tumor progression and metastasis *Nat Med* **5**, 793-802
25. Pikas, D. S., Li, J. P., Vlodavsky, I., and Lindahl, U. (1998) Substrate specificity of heparanases from human hepatoma and platelets *J Biol Chem* **273**, 18770-18777

26. Gong, F., Jemth, P., Escobar Galvis, M. L., Vlodavsky, I., Horner, A., Lindahl, U., and Li, J. P. (2003) Processing of macromolecular heparin by heparanase *J Biol Chem* **278**, 35152-35158
27. Balazs, E. A. (2004) Viscosupplementation for treatment of osteoarthritis: from initial discovery to current status and results *Surg Technol Int* **12**, 278-289
28. Goa, K. L., and Benfield, P. (1994) Hyaluronic acid. A review of its pharmacology and use as a surgical aid in ophthalmology, and its therapeutic potential in joint disease and wound healing *Drugs* **47**, 536-566
29. Stern, R. (2004) Hyaluronan catabolism: a new metabolic pathway *Eur J Cell Biol* **83**, 317-325
30. DeAngelis, P. L., and White, C. L. (2002) Identification and molecular cloning of a heparosan synthase from *Pasteurella multocida* type D *J Biol Chem* **277**, 7209-7213
31. Barzu, T., van Rijn, J. L., Petitou, M., Tobelem, G., and Caen, J. P. (1987) Heparin degradation in the endothelial cells *Thromb Res* **47**, 601-609
32. Vann, W. F., Schmidt, M. A., Jann, B., and Jann, K. (1981) The structure of the capsular polysaccharide (K5 antigen) of urinary-tract-infective *Escherichia coli* 010:K5:H4. A polymer similar to desulfo-heparin *Eur J Biochem* **116**, 359-364
33. Capila, I., and Linhardt, R. J. (2002) Heparin-protein interactions *Angew Chem Int Ed Engl* **41**, 391-412
34. Tammi, M. I., Day, A. J., and Turley, E. A. (2002) Hyaluronan and homeostasis: a balancing act *J Biol Chem* **277**, 4581-4584
35. Stern, R., Asari, A. A., and Sugahara, K. N. (2006) Hyaluronan fragments: an information-rich system *Eur J Cell Biol* **85**, 699-715
36. Powell, J. D., and Horton, M. R. (2005) Threat matrix: low-molecular-weight hyaluronan (HA) as a danger signal *Immunol Res* **31**, 207-218
37. West, D. C., and Kumar, S. (1989) Hyaluronan and angiogenesis *Ciba Found Symp* **143**, 187-201; discussion 201-187, 281-185
38. Trochon, V., Mabilat, C., Bertrand, P., Legrand, Y., Smadja-Joffe, F., Soria, C., Delpech, B., and Lu, H. (1996) Evidence of involvement of CD44 in endothelial cell proliferation, migration and angiogenesis in vitro *Int J Cancer* **66**, 664-668

39. Scheibner, K. A., Lutz, M. A., Boodoo, S., Fenton, M. J., Powell, J. D., and Horton, M. R. (2006) Hyaluronan fragments act as an endogenous danger signal by engaging TLR2 *J Immunol* **177**, 1272-1281
40. Hodson, N., Griffiths, G., Cook, N., Pourhossein, M., Gottfridson, E., Lind, T., Lidholt, K., and Roberts, I. S. (2000) Identification that KfiA, a protein essential for the biosynthesis of the Escherichia coli K5 capsular polysaccharide, is an alpha -UDP-GlcNAc glycosyltransferase. The formation of a membrane-associated K5 biosynthetic complex requires KfiA, KfiB, and KfiC *J Biol Chem* **275**, 27311-27315
41. Monheit, G. D., and Coleman, K. M. (2006) Hyaluronic acid fillers *Dermatol Ther* **19**, 141-150
42. Li, M., Timmons, R. B., and Kinsel, G. R. (2005) Radio frequency plasma polymer coatings for affinity capture MALDI mass spectrometry *Anal Chem* **77**, 350-353
43. Su, S. H., Chao, R. Y., Landau, C. L., Nelson, K. D., Timmons, R. B., Meidell, R. S., and Eberhart, R. C. (2003) Expandable bioresorbable endovascular stent. I. Fabrication and properties *Ann Biomed Eng* **31**, 667-677
44. Bitter, T., and Muir, H. M. (1962) A modified uronic acid carbazole reaction *Anal Biochem* **4**, 330-334
45. Lee, H. G., and Cowman, M. K. (1994) An agarose gel electrophoretic method for analysis of hyaluronan molecular weight distribution *Anal Biochem* **219**, 278-287
46. Tracy, B. S., Avci, F. Y., Linhardt, R. J., and DeAngelis, P. L. (2007) Acceptor specificity of the Pasteurella hyaluronan and chondroitin synthases and production of chimeric glycosaminoglycans *J Biol Chem* **282**, 337-344
47. Deangelis PL, White CL. (2004) Identification of a distinct, cryptic heparosan synthase from Pasteurella multocida types A, D, and F. *J Bacteriol.* **186**, 8529-32.

In the claims which follow and in the preceding description of the invention, except where the context requires otherwise due to express language or necessary implication, the word “comprise” or variations such as “comprises” or “comprising” is used in an inclusive sense, i.e. to specify the presence of the stated features but not to preclude the presence or addition of further features in various embodiments of the invention.

It is to be understood that, if any prior art publication is referred to herein, such reference does not constitute an admission that the publication forms a part of the common general knowledge in the art, in Australia or any other country.

What is claimed is:

1. A method for recombinantly producing a high molecular weight heparosan polymer, the method comprising the steps of:

culturing a recombinant host cell containing a nucleotide sequence encoding a *Pasteurella* heparosan synthase under conditions appropriate for the expression of the heparosan synthase; and

isolating heparosan polymer produced by the heparosan synthase, wherein the isolated heparosan polymer is biocompatible with a mammalian patient and biologically inert within extracellular compartments of a mammalian patient, and wherein the isolated heparosan polymer is represented by the structure $(-\text{GlcUA-}\beta\text{1,4-GlcNAc-}\alpha\text{1,4-})_n$, wherein n is a positive integer greater than or equal to 2,000.

2. The method of Claim 1, wherein culturing the recombinant host cells comprises the steps of:

culturing a recombinant host cell containing a nucleotide sequence encoding a polypeptide having heparosan synthase activity under conditions appropriate for the expression of the heparosan synthase, wherein at least one of:

- (a) the polypeptide having heparosan synthase activity is at least 90% identical to at least one of SEQ ID NOS:2, 4, and 6-8, and the nucleotide sequence encoding the polypeptide has been gene-optimized for expression in the recombinant host cell;
- (b) the polypeptide having heparosan synthase activity has 1-20 amino acid additions, deletions, and/or substitutions when compared to at least one of SEQ ID NOS:2, 4, and 6-8, and the nucleotide sequence encoding the polypeptide has been gene-optimized for expression in the recombinant host cell;
- (c) the polypeptide is encoded by the nucleotide sequence of at least one of SEQ ID NOS:9-11;
- (d) the polypeptide is encoded by a nucleotide sequence that is at least 90% identical to at least one of SEQ ID NOS:9-11; and

isolating heparosan polymer produced by the heparosan synthase, wherein the isolated heparosan polymer is biocompatible with a mammalian patient and biologically inert within extracellular compartments of a mammalian patient, and wherein the isolated heparosan polymer is represented by the structure $(\text{-GlcUA-}\beta\text{1,4-GlcNAc-}\alpha\text{1,4-})_n$, wherein n is a positive integer greater than or equal to 2,000.

3. The method of claim 1, wherein the isolated heparosan polymer has a value for n in a range of from about 2,000 to about 17,000.
4. The method of any one of claims 1-3, further comprising attaching the isolated heparosan polymer to at least a portion of a surface of a substrate.
5. The method of claim 4, wherein the substrate is selected from the group consisting of silica, silicon, semiconductors, glass, polymers, nanotubes, nanoparticles, organic compounds, inorganic compounds, metals, and combinations thereof.
6. The method of claim 4, wherein at least a portion of the substrate is a metal selected from the group consisting of gold, copper, stainless steel, nickel, aluminum, titanium, thermosensitive alloys, and combinations thereof.
7. The method of any one of claims 1-6, further comprising the step of crosslinking the isolated heparosan polymer.
8. The method of any one of claims 1-7, wherein the recombinant host cell is an *E. coli* recombinant host cell.
9. An isolated nucleotide sequence encoding a polypeptide having heparosan synthase activity, wherein at least one of:
 - (a) the polypeptide having heparosan synthase activity is at least 90% identical to at least one of SEQ ID NOS:2, 4, and 6-8, and the nucleotide sequence encoding

- the polypeptide has been gene-optimized for expression in the recombinant host cell; and
- (b) the polypeptide having heparosan synthase activity has 1-20 amino acid additions, deletions, and/or substitutions when compared to at least one of SEQ ID NOS:2, 4, and 6-8, and the nucleotide sequence encoding the polypeptide has been gene-optimized for expression in the recombinant host cell;
 - (c) the polypeptide is encoded by the nucleotide sequence of at least one of SEQ ID NOS:9-11; and
 - (d) the polypeptide is encoded by a nucleotide sequence that is at least 90% identical to at least one of SEQ ID NOS:9-11.
10. A recombinant host cell, comprising the isolated nucleotide sequence of claim 9.
11. A method of augmenting tissue in a mammalian patient, comprising the steps of: administering an effective amount of a biomaterial composition to a mammalian patient, the biomaterial composition comprising an isolated heparosan polymer that is biocompatible with the mammalian patient and biologically inert in extracellular compartments of the mammalian patient, wherein the isolated heparosan polymer is represented by the structure $(\text{-GlcUA-}\beta\text{1,4-GlcNAc-}\alpha\text{1,4-})_n$, wherein n is a positive integer greater than or equal to 2,000.
12. The method of claim 11, wherein the isolated heparosan polymer has a value for n in a range of from about 2,000 to about 17,000.
13. The method of any one of claims 11-12, wherein the biomaterial composition is in a gel, semi-solid, liquid, and/or particulate state.
14. The method of any one of claims 11-13, wherein the biomaterial composition further comprises a substrate, and wherein the isolated heparosan polymer is attached to the substrate.

15. A biomaterial composition, the composition comprising:
an isolated heparosan polymer, wherein the isolated heparosan polymer is biocompatible with a mammalian patient and biologically inert in extracellular compartments of a mammalian patient, the isolated heparosan polymer being represented by the structure $(-\text{GlcUA-}\beta\text{1,4-GlcNAc-}\alpha\text{1,4-})_n$, wherein n is a positive integer greater than or equal to 2,000.
16. The biomaterial composition of claim 15, wherein n is in a range of from about 2,000 to about 17,000.
17. The biomaterial composition of any of claims 15-16, wherein the biomaterial is in a gel, semi-solid, and/or particulate state.
18. The biomaterial composition of any one of claims 15-17, wherein the isolated heparosan polymer is attached to a substrate.
19. The biomaterial composition of claim 18, wherein the substrate is selected from the group consisting of silica, silicon, semiconductors, glass, polymers, nanotubes, nanoparticles, organic compounds, inorganic compounds, metals, and combinations thereof.
20. The biomaterial composition of claim 18, wherein at least a portion of the substrate is a metal selected from the group consisting of gold, copper, stainless steel, nickel, aluminum, titanium, thermosensitive alloys, and combinations thereof.
21. Use of a biomaterial composition of any one of claims 15-20 in the manufacture of a medicament for augmenting tissue in a mammalian patient.

pmHS1	10	20	30	40	50	60	70	80	90
pmHS1-opt1	10	20	30	40	50	60	70	80	90
pmHS1-opt2	10	20	30	40	50	60	70	80	90
pmHS1	100	110	120	130	140	150	160	170	180
pmHS1-opt1	100	110	120	130	140	150	160	170	180
pmHS1-opt2	100	110	120	130	140	150	160	170	180
pmHS1	190	200	210	220	230	240	250	260	270
pmHS1-opt1	190	200	210	220	230	240	250	260	270
pmHS1-opt2	190	200	210	220	230	240	250	260	270
pmHS1	280	290	300	310	320	330	340	350	360
pmHS1-opt1	280	290	300	310	320	330	340	350	360
pmHS1-opt2	280	290	300	310	320	330	340	350	360
pmHS1	370	380	390	400	410	420	430	440	450
pmHS1-opt1	370	380	390	400	410	420	430	440	450
pmHS1-opt2	370	380	390	400	410	420	430	440	450
pmHS1	460	470	480	490	500	510	520	530	540
pmHS1-opt1	460	470	480	490	500	510	520	530	540
pmHS1-opt2	460	470	480	490	500	510	520	530	540
pmHS1	550	560	570	580	590	600	610	620	630
pmHS1-opt1	550	560	570	580	590	600	610	620	630
pmHS1-opt2	550	560	570	580	590	600	610	620	630
pmHS1	640	650	660	670	680	690	700	710	720
pmHS1-opt1	640	650	660	670	680	690	700	710	720
pmHS1-opt2	640	650	660	670	680	690	700	710	720
pmHS1	730	740	750	760	770	780	790	800	810
pmHS1-opt1	730	740	750	760	770	780	790	800	810
pmHS1-opt2	730	740	750	760	770	780	790	800	810
pmHS1	820	830	840	850	860	870	880	890	900
pmHS1-opt1	820	830	840	850	860	870	880	890	900
pmHS1-opt2	820	830	840	850	860	870	880	890	900
pmHS1	910	920	930	940	950	960	970	980	990
pmHS1-opt1	910	920	930	940	950	960	970	980	990
pmHS1-opt2	910	920	930	940	950	960	970	980	990

FIGURE 1A

pmHS1	840	850	860	870	880	890	900	910	920
pmHS1-opt1	GACAAATTAATC	ATGAATCCAA	AAATTAAT	AAAGGAAAT	TAATGA	AAATTAAT	AAAGGAAAT	TAATGA	AAATTAAT
pmHS1-opt2	GACAGAAATATC	ATGAATCCAA	AAATTAAT	AAAGGAAAT	TAATGA	AAATTAAT	AAAGGAAAT	TAATGA	AAATTAAT
pmHS1	1030	1040	1050	1060	1070	1080	1090	1100	1110
pmHS1-opt1	TCAATGA	CCATTCCT	TAATGA	AAATTAAT	AAAGGAAAT	TAATGA	AAATTAAT	AAAGGAAAT	TAATGA
pmHS1-opt2	TCAATGA	CCATTCCT	TAATGA	AAATTAAT	AAAGGAAAT	TAATGA	AAATTAAT	AAAGGAAAT	TAATGA
pmHS1	1110	1120	1130	1140	1150	1160	1170	1180	1190
pmHS1-opt1	TCAATGA	CCATTCCT	TAATGA	AAATTAAT	AAAGGAAAT	TAATGA	AAATTAAT	AAAGGAAAT	TAATGA
pmHS1-opt2	TCAATGA	CCATTCCT	TAATGA	AAATTAAT	AAAGGAAAT	TAATGA	AAATTAAT	AAAGGAAAT	TAATGA
pmHS1	1200	1210	1220	1230	1240	1250	1260	1270	1280
pmHS1-opt1	AAATGA	CCATTCCT	TAATGA	AAATTAAT	AAAGGAAAT	TAATGA	AAATTAAT	AAAGGAAAT	TAATGA
pmHS1-opt2	AAATGA	CCATTCCT	TAATGA	AAATTAAT	AAAGGAAAT	TAATGA	AAATTAAT	AAAGGAAAT	TAATGA
pmHS1	1290	1300	1310	1320	1330	1340	1350	1360	1370
pmHS1-opt1	AAATGA	CCATTCCT	TAATGA	AAATTAAT	AAAGGAAAT	TAATGA	AAATTAAT	AAAGGAAAT	TAATGA
pmHS1-opt2	AAATGA	CCATTCCT	TAATGA	AAATTAAT	AAAGGAAAT	TAATGA	AAATTAAT	AAAGGAAAT	TAATGA
pmHS1	1380	1390	1400	1410	1420	1430	1440	1450	1460
pmHS1-opt1	AAATGA	CCATTCCT	TAATGA	AAATTAAT	AAAGGAAAT	TAATGA	AAATTAAT	AAAGGAAAT	TAATGA
pmHS1-opt2	AAATGA	CCATTCCT	TAATGA	AAATTAAT	AAAGGAAAT	TAATGA	AAATTAAT	AAAGGAAAT	TAATGA
pmHS1	1470	1480	1490	1500	1510	1520	1530	1540	1550
pmHS1-opt1	AAATGA	CCATTCCT	TAATGA	AAATTAAT	AAAGGAAAT	TAATGA	AAATTAAT	AAAGGAAAT	TAATGA
pmHS1-opt2	AAATGA	CCATTCCT	TAATGA	AAATTAAT	AAAGGAAAT	TAATGA	AAATTAAT	AAAGGAAAT	TAATGA
pmHS1	1560	1570	1580	1590	1600	1610	1620	1630	1640
pmHS1-opt1	AAATGA	CCATTCCT	TAATGA	AAATTAAT	AAAGGAAAT	TAATGA	AAATTAAT	AAAGGAAAT	TAATGA
pmHS1-opt2	AAATGA	CCATTCCT	TAATGA	AAATTAAT	AAAGGAAAT	TAATGA	AAATTAAT	AAAGGAAAT	TAATGA
pmHS1	1650	1660	1670	1680	1690	1700	1710	1720	1730
pmHS1-opt1	AAATGA	CCATTCCT	TAATGA	AAATTAAT	AAAGGAAAT	TAATGA	AAATTAAT	AAAGGAAAT	TAATGA
pmHS1-opt2	AAATGA	CCATTCCT	TAATGA	AAATTAAT	AAAGGAAAT	TAATGA	AAATTAAT	AAAGGAAAT	TAATGA
pmHS1	1740	1750	1760	1770	1780	1790	1800	1810	1820
pmHS1-opt1	AAATGA	CCATTCCT	TAATGA	AAATTAAT	AAAGGAAAT	TAATGA	AAATTAAT	AAAGGAAAT	TAATGA
pmHS1-opt2	AAATGA	CCATTCCT	TAATGA	AAATTAAT	AAAGGAAAT	TAATGA	AAATTAAT	AAAGGAAAT	TAATGA
pmHS1	1830	1840	1850	1860	1870	1880	1890	1900	1910
pmHS1-opt1	AAATGA	CCATTCCT	TAATGA	AAATTAAT	AAAGGAAAT	TAATGA	AAATTAAT	AAAGGAAAT	TAATGA
pmHS1-opt2	AAATGA	CCATTCCT	TAATGA	AAATTAAT	AAAGGAAAT	TAATGA	AAATTAAT	AAAGGAAAT	TAATGA

FIGURE 1A (Continued)

FIGURE 1B

SUBSTITUTE SHEET (RULE 26)

PmHS-opt3 37 ATGGGTACCTCACTGTTTAAACGTGCTACGGAACTTTTTTAAAAGCGGAACTACAAAGAT
Native pmHS 37 ATGGGTACCTCACTGTTTAAACGTGCTACAGAACTTTTTTAAAAGCGGCAACTACAAAGAT

PmHS-opt3 97 GCTCTTACATTGTACGAAAACATCGCCAAAATCTATGGCAGCGAATCTCTGGTTAAATAC
Native pmHS 97 GCTCTTACGTTGTACGAAAACATCGCCAAAATCTACGGAAGCGAATCTCTGGTTAAATAC

PmHS-opt3 157 AACATCGATATCTGCAAGAAAAATATCAGCAATCAAAAAGCAACAAAATCGAAGAAGAT
Native pmHS 157 AACATCGATATCTGCAAGAAAAATATTACACAATCAAAAAGCAACAAAATCGAAGAAGAT

PmHS-opt3 217 AACATCTCAGGAGAAAACAAATTTTCTGTTTCAATCAAAGATTTATATAACGAAATTAGC
Native pmHS 217 AACATCTCAGGCGAAAACAAATTTTCTGTTTCAATCAAAGATTTATATAACGAAATTAGC

PmHS-opt3 277 AATTCTGAATTGGGCATCACAAAAGAACGGTTAGGCGCACCGCCTTTGGTGTCTATTATC
Native pmHS 277 AATTCTGAATTGGGCATCACAAAAGAACGGTTAGGAGCTCCGCCTTTGGTGTCTATTATC

PmHS-opt3 337 ATGACATCACATAACACGGAAAAATTTATCGAAGCCAGCATCAACTCTCTGCTTTTACAG
Native pmHS 337 ATGACATCACATAACACGGAAAAATTTATCGAAGCCAGCATCAACTCTCTGCTTTTGCAG

PmHS-opt3 397 ACATACAACAACCTTGAAGTCATCGTTGTGGATGATTACTCTACAGATAAAACGTTTCAA
Native pmHS 397 ACATACAACAACCTTGAAGTCATCGTTGTGGATGATTACTCTACAGATAAAACGTTTCAA

PmHS-opt3 457 ATCGCTTCAAGAATCGCCAATTCAACAAGCAAAGTAAAAACGTTTCGCTTAAACAGCAAC
Native pmHS 457 ATCGCTTCAAGAATCGCCAATTCAACAAGCAAAGTAAAAACGTTTCGCTTAAACAGCAAC

PmHS-opt3 517 TTGGGCACATACTTTGCTAAAAACACGGGCATCTTAAAAAGCAAAGGAGATATCATTTTC
Native pmHS 517 TTGGGAACATACTTTGCTAAAAACACGGGCATCTTGAAAAGCAAAGGAGATATCATTTTC

PmHS-opt3 577 TTTCAGGATTCTGATGATGTCTGCCATCATGAAAGAATTGAACGCTGTGTAAATGCCTTG
Native pmHS 577 TTTCAGGATTCTGATGATGTCTGCCATCATGAAAGAATTGAACGCTGTGTAAATGCCTTG

PmHS-opt3 637 CTGAGCAACAAAGATAATATTGCAGTCCGTTGCGCGTATTCTCGGATCAACCTGGAAACA
Native pmHS 637 CTGAGCAACAAAGATAATATTGCAGTCCGTTGCGCGTATTCTCGGATCAACCTGGAAACA

PmHS-opt3 697 CAAAACATCATCAAAGTAAACGATAACAAATACAAATTGGGCCTGATTACGCTTGGAGTT
Native pmHS 697 CAAAACATCATCAAAGTAAACGATAACAAATACAAATTGGGCCTGATTACGCTTGGAGTT

PmHS-opt3 757 TATCGTAAAGTGTTTAAACGAAATCGGCTTTTTCAATTGTACAACGAAAGCCTCTGATGAT
Native pmHS 757 TATCGTAAAGTGTTTAAACGAAATCGGCTTTTTCAATTGTACAACGAAAGCCTCTGATGAT

PmHS-opt3 817 GAATTTTACCATAGAAATCATCAAATACTATGGAAAAATCGCATTAATAACCTGTTTCTG
Native pmHS 817 GAATTTTACCATAGAAATCATCAAATACTATGGAAAAATCGCATTAATAACCTGTTTCTG

PmHS-opt3 877 CCGTTGTACTACAACACAATGCGTGAAGATTCATTATTTAGCGATATGGTCGAATGGGTA
Native pmHS 877 CCGTTGTACTACAACACAATGCGTGAAGATTCATTATTTAGCGATATGGTCGAATGGGTA

PmHS-opt3 937 GATGAAAACAACATCAAACAAAAACGTCAGATGCACGGCAGAACTACTTGCATGAATTT
Native pmHS 937 GATGAAAACAACATCAAACAAAAACGTCAGATGCACGGCAGAACTACTTGCATGAATTT

FIGURE 1C

PmHS-opt3 997 CAAAAAATCCATAACGAACGTAAACTGAACGAACCTAAAGAAATTTTCTAGCTTTCCGAGA
Native pmHS 997 CAAAAAATCCATAACGAACGTAAACTGAACGAACCTAAAGAAATTTTCTAGCTTTCCGCGG

PmHS-opt3 1057 ~~ATCC~~ATCATGATGCGCTGCCTATCTCAAAAGAAATGTCTAAACTTTCAAACCCGAAAAATCCCT
Native pmHS 1057 ATCCATGATGCGCTGCCTATCTCAAAAGAAATGTCTAAACTTTCAAACCCGAAAAATCCCT

PmHS-opt3 1117 GTTTACATCAACATTTGCTCAATTCCGTCTCGCATCAAACAATTACAGTACACAAATCGGA
Native pmHS 1117 GTTTACATCAACATCTGCAGCATTCCGTCTCGCATCAAACAATTACAGTATACAATTGGC

PmHS-opt3 1177 GTGTTGAAAAACCAGTGTGATCATTTTTCATATCTACTTGGATGGCTATCCGGAAGTTCCT
Native pmHS 1177 GTGTTGAAAAACCAGTGTGATCATTTTTCATATCTACTTGGATGGCTATCCGGAAGTTCCT

PmHS-opt3 1237 GATTTTATCAAAAAATTGGGAAACAAAGCAACGGTGATCAACTGCCAAAACAAAAACGAA
Native pmHS 1237 GATTTTATCAAAAAATTGGGAAACAAAGCAACGGTGATCAACTGCCAAAACAAAAACGAA

PmHS-opt3 1297 AGCATCAGAGATAACGGCAAATTTATCCTTTTGAAGAAAATTGATCAAAGAAAACAAAGAT
Native pmHS 1297 AGCATCAGAGATAACGGCAAATTTATCCTTTTGGAAAAATTGATCAAAGAAAACAAAGAT

PmHS-opt3 1357 GGATACTACATCACATGTGATGATGATATTGCTATCCTGCGGATTATATTAATACGATG
Native pmHS 1357 GGATACTACATCACATGTGATGATGATATTGCTATCCTGCGGATTATATTAATACGATG

PmHS-opt3 1417 ATTAAGAAAATTAACAAATACAACGATAAAGCAGCGATCGGCCTGCATGGAGTTATCTTT
Native pmHS 1417 ATTAAGAAAATTAACAAATACAACGATAAAGCAGCGATCGGCCTGCATGGAGTTATCTTT

PmHS-opt3 1477 CCGTCTCGTGTGAACAAATACTTTTCAAGCGATCGGATCGTCTACAACTTTTCAGAAACCT
Native pmHS 1477 CCGTCTCGTGTGAACAAATACTTTTCAAGCGATCGGATCGTCTACAACTTTTCAGAAACCT

PmHS-opt3 1537 ~~TTAG~~AAAAACGATACAGCAGTAAACATCTTGGGCACAGGAACGGTCGCGTTTAGAGTATCA
Native pmHS 1537 TTGAAAAACGATACAGCAGTAAACATCTTGGGCACAGGAACGGTCGCGTTTAGAGTATCA

PmHS-opt3 1597 ATCTTTAACAAATTTTCTCTGTCTGATTTTGAACATCCGGGCATGGTTGATATCTACTTT
Native pmHS 1597 ATCTTTAACAAATTTTCTCTGTCTGATTTTGAACATCCGGGCATGGTTGATATCTACTTT


PmHS-opt3 1657 AGCATCCTGTGCAAGAAAAATAACATCCTTCAAGTGTGTATCTCAAGACCTAGCAATTGG
Native pmHS 1657 AGCATCCTGTGCAAGAAAAATAACATCCTTCAAGTGTGTATCTCAAGACCTAGCAATTGG

PmHS-opt3 1717 CTGACAGAAGATAACAAAAACACAGAAACGCTTTTTTCATGAATTTCAAACCCGCGATGAA
Native pmHS 1717 CTGACAGAAGATAACAAAAACACAGAAACGCTTTTTTCATGAATTTCAAACCCGCGATGAA

PmHS-opt3 1777 ATCCAGAGCAAACCTTATCATCTCTAACAACCCGTGGGGATATTCTTCAATCTACCCCTTG
Native pmHS 1777 ATCCAGAGCAAACCTTATCATCTCTAACAACCCGTGGGGATACTCTTCAATCTACCCCTTG

PmHS-opt3 1837 CTGAACAACAACGCAAACCTACTCAGAACTGATCCCGTGTCTTAGCTTTTATAACGAATAA
Native pmHS 1837 CTGAACAACAACGCAAACCTACTCAGAACTGATCCCGTGTCTTAGCTTTTATAACGAATAA

FIGURE 1C (continued)

**FIGURE 2**





FIGURE 3

**FIGURE 4**




FIGURE 5

SEQUENCE LISTING

<110> DeAngelis, Paul
Pummill, Philip
Visser, Regina

<120> HIGH MOLECULAR WEIGHT HEPAROSAN POLYMERS AND METHODS OF
PRODUCTION AND USE THEREOF

<130> 45992.042wo

<150> 61/617,952
<151> 2012-03-30

<160> 11

<170> PatentIn version 3.5

<210> 1
<211> 1851
<212> DNA
<213> *Pasteurella multocida*

<400> 1
atgagcttat ttaaactgct tactgagcta ttttaagtcag gaaactataa agatgcacta 60
actctatatg aaaaatatag taaaatttat ggttcagaaa gccttgtaa atataatatt 120
gatatatgta aaaaaaatat aacacaatca aaaagtaata aaatagaaga agataatatt 180
tctggagaaa acaaattttc agtatcaata aaagatctat ataacgaaat aagcaatagt 240
gaattagggg ttacaaaaga aagactagga gccccccctc tagtcagtat tataatgact 300
tctcataata cagaaaaatt cattgaagcc tcaattaatt cactattatt gcaaacatac 360
aataacttag aagttatcgt tgtagatgat tatagcacag ataaaacatt tcagatcgca 420
tccagaatag caaactctac aagtaaagta aaaacattcc gattaaactc aaatctaggg 480
acatactttg cgaaaaatac aggaatttta aagtctaaag gagatattat tttctttcag 540
gatagcgatg atgtatgtca ccatgaaaga atcgaaagat gtgttaatgc attattatcg 600
aataaagata atatagctgt tagatgtgca tattctagaa taaatctaga aacacaaaat 660
ataataaaaag ttaatgataa taaatacaaa ttaggattaa taactttagg cgtttataga 720
aaagtattta atgaaattgg tttttttaac tgcacaacca aagcatcgga tgatgaattt 780
tatcatagaa taattaaata ctatggtaaa aataggataa ataacttatt tctaccactg 840
tattataaca caatgcgtga agattcatta ttttctgata tgggtgagtg ggtagatgaa 900
aataatataa agcaaaaac ctctgatgct agacaaaatt atctccatga attccaaaaa 960
atacacaatg aaaggaaatt aaatgaatta aaagagattt ttagctttcc tagaattcat 1020
gacgccttac ctatatcaaa agaaatgagt aagctcagca accctaaaat tcctgtttat 1080
ataaatatat gctcaatacc ttcaagaata aaacaacttc aatacactat tggagtacta 1140
aaaaaccaat gcgatcattt tcatatttat cttgatggat atccagaagt acctgatttt 1200
ataaaaaaac tagggaataa agcgaccgtt attaattgtc aaaacaaaaa tgagtctatt 1260
agagataatg gaaagtttat tctattagaa aaacttataa aggaaaataa agatggatat 1320
tatataactt gtgatgatga tatccggtat cctgctgact acacaaacac tatgataaaa 1380
aaaattaata aatacaatga taaagcagca attggattac atggtgttat attcccaagt 1440
agagtcaaca agtatttttc atcagacaga attgtctata attttcaaaa accttagaa 1500
aatgatactg ctgtaaatat attaggaact ggaactgttg ctttagagt atctattttt 1560
aataaatttt ctctatctga ttttgagcat cctggcatgg tagatatcta tttttctata 1620
ctatgtaaga aaacaatat actccaagtt tgtatatcac gaccatcgaa ttggctaaca 1680
gaagataaca aaacactga gacctattt catgaattcc aaaatagaga tgaaatacaa 1740

agtaaaactca ttatttcaaa caacccttgg ggataactcaa gtatatatcc actattaaat 1800
aataatgcta attattctga acttattccg tgtttatctt tttataacga g 1851

<210> 2
<211> 615
<212> PRT
<213> Pasteurella multocida

<400> 2

Met Ser Leu Phe Lys Arg Ala Thr Glu Leu Phe Lys Ser Gly Asn Tyr
1 5 10 15
Lys Asp Ala Leu Thr Leu Tyr Glu Asn Ile Ala Lys Ile Tyr Gly Ser
20 25 30
Glu Ser Leu Val Lys Tyr Asn Ile Asp Ile Cys Lys Lys Asn Ile Thr
35 40 45
Gln Ser Lys Ser Asn Lys Ile Glu Glu Asp Asn Ile Ser Gly Glu Asn
50 55 60
Lys Phe Ser Val Ser Ile Lys Asp Leu Tyr Asn Glu Ile Ser Asn Ser
65 70 75 80
Glu Leu Gly Ile Thr Lys Glu Arg Leu Gly Ala Pro Pro Leu Val Ser
85 90 95
Ile Ile Met Thr Ser His Asn Thr Glu Lys Phe Ile Glu Ala Ser Ile
100 105 110
Asn Ser Leu Leu Leu Gln Thr Tyr Asn Leu Glu Val Ile Val Val Asp
115 120 125
Asp Tyr Ser Thr Asp Lys Thr Phe Gln Ile Ala Ser Arg Ile Ala Asn
130 135 140
Ser Thr Ser Lys Val Lys Thr Phe Arg Leu Asn Ser Asn Leu Gly Thr
145 150 155 160
Tyr Phe Ala Lys Asn Thr Gly Ile Leu Lys Ser Lys Gly Asp Ile Ile
165 170 175
Phe Phe Gln Ser Asp Asp Val Cys His His Glu Arg Ile Glu Arg Cys
180 185 190
Val Asn Ala Leu Leu Ser Asn Lys Asp Asn Ile Ala Val Arg Cys Ala
195 200 205
Tyr Ser Arg Ile Asn Leu Glu Thr Gln Asn Ile Ile Lys Val Asn Asp
210 215 220
Asn Lys Tyr Lys Leu Gly Leu Ile Thr Leu Gly Val Tyr Arg Lys Val
225 230 235 240
Phe Asn Glu Ile Gly Phe Phe Asn Cys Thr Thr Lys Ala Ser Asp Asp
245 250 255
Glu Phe Tyr His Arg Ile Ile Lys Tyr Tyr Gly Lys Asn Arg Ile Asn
260 265 270

Asn Leu Phe Leu Pro Leu Tyr Tyr Asn Thr Met Arg Glu Asp Ser Leu
 275 280 285
 Phe Ser Asp Met Val Glu Trp Val Asp Glu Asn Asn Ile Lys Gln Lys
 290 295 300
 Thr Ser Asp Ala Arg Gln Asn Tyr Leu His Glu Phe Gln Lys Ile His
 305 310 315 320
 Asn Glu Arg Lys Leu Asn Glu Leu Lys Glu Ile Phe Ser Phe Pro Arg
 325 330 335
 Ile His Asp Ala Leu Pro Ile Ser Lys Glu Met Ser Lys Leu Ser Asn
 340 345 350
 Pro Lys Ile Pro Val Tyr Ile Asn Ile Cys Ser Ile Pro Ser Arg Ile
 355 360 365
 Lys Gln Leu Gln Tyr Thr Ile Gly Val Leu Lys Asn Gln Cys Asp His
 370 375 380
 Phe His Ile Tyr Leu Asp Gly Tyr Pro Glu Val Pro Asp Phe Ile Lys
 385 390 395 400
 Lys Leu Gly Asn Lys Ala Thr Val Ile Asn Cys Gln Asn Lys Asn Glu
 405 410 415
 Ser Ile Arg Asp Asn Gly Lys Phe Ile Leu Leu Glu Lys Leu Ile Lys
 420 425 430
 Glu Asn Lys Asp Gly Tyr Tyr Ile Thr Cys Asp Asp Asp Ile Arg Tyr
 435 440 445
 Pro Ala Asp Tyr Thr Asn Thr Met Ile Lys Lys Ile Asn Lys Tyr Asn
 450 455 460
 Asp Lys Ala Ala Ile Gly Leu His Gly Val Ile Phe Pro Ser Arg Val
 465 470 475 480
 Asn Lys Tyr Phe Ser Ser Asp Arg Ile Val Tyr Asn Phe Gln Lys Pro
 485 490 495
 Leu Glu Asn Asp Thr Ala Val Asn Ile Leu Gly Thr Gly Thr Val Ala
 500 505 510
 Phe Arg Val Ser Ile Phe Asn Lys Phe Ser Leu Ser Asp Phe Glu His
 515 520 525
 Pro Gly Met Val Asp Ile Tyr Phe Ser Ile Leu Cys Lys Lys Asn Asn
 530 535 540
 Ile Leu Gln Val Cys Ile Ser Arg Pro Ser Asn Trp Leu Thr Glu Asp
 545 550 555 560
 Asn Lys Asn Thr Glu Thr Leu Phe His Glu Phe Gln Asn Arg Asp Glu
 565 570 575
 Ile Gln Ser Lys Leu Ile Ile Ser Asn Asn Pro Trp Gly Tyr Ser Ser
 580 585 590
 Ile Tyr Pro Leu Leu Asn Asn Asn Ala Asn Tyr Ser Glu Leu Ile Pro

Cys Leu Ser Phe Tyr Asn Gln
610

595

600

605

<210> 3
<211> 1940
<212> DNA
<213> Pasteurella multocida

<400> 3

aacagggat aaggtcagta aatttaggat gatttttgac taatggataa atacttgaat
120 atcccatgg accgtttccc atgatcagct gattttgttg ctcacatgtg tctcgatat
180 gatgatagag tgttttcgctg tctctatatat cttccgttag ccagtttgcg ggtccttgaaa
240 tacaaattcg aagaatatata ttttttcttac accaaggagga gaaatagataa tcagcccatgc
300 ctgaattgggt aaggtccagaa agagaaattt gattaaagag actgacctca aagcttaacag
360 ttccgtgacc taatatcatgg accgctttgt ctttttccag aggtttatag aagcttatata
420 ccagtcttacc cgcgcgaaaaa tattttgttcca ttctaatggg aaagagaatg ccgtgtaaaac
480 caataaacgcg ttatcatcag tatcttctca gcttcttgat catcgttatg atgtaatcgc
540 ttggatagat aatgttcatca tcacaggtta tataatatcc atcttgattt ttttcaatcca
600 acctttccag taaaatgaaat ttgccattat ctctaattga gtatatctta tcttttgcaat
660 gaaacaacggt tgcctttatata cctaatttt ttatgaagtc agggattttct acatagcccat
720 caagataaat atgaaaaatga tcaaattgat tttttatgat gccgatataa cgtcgttaatt
780 ggcattatct tgaagggaata gaaacaatat tgatatataa c aggaatctta ggaattggaca
840 acttaacctcat ttcttgttgtt acttggttaagg catcgttaaat acgaggggaat tgaaaaaagat
900 ttttgaaatc atgttgaggca gtttctgttat gcatcgccttg aaacaggggtt gcaataatgtt
960 gcttggtatc agaatcttcc tgttatatatg tatgatgtgc tatcccatcca accatatcag
1020 taataaagaa gttttctctc atttgttgtt agtataaagg caagagtaaa ttttttatatt
1080 tttcttttcc ataatatttc gcaattctat gaaaaaaatc atcatcttgag cctttagctg
1140 tacaattgaa gaaacccaat tcttgaaata cttttcttggt catatcccaag gttataaaac
1200 ctaattctata atccatatata ttgaatttaa tgatatgttg tgttcttggt gctagttcttg
1260 agtatgcaca acgaacagca atagtctctt tattagctaa taatatattt acacatcttt
1320 ctattcttcc atgatgacat acatcatcac tatcttgaaa gaaaaataatg tcaacctttag
1380 attttaatat gcccttgatat ttttccgaaagt aagttccctag gtttgaaatt aatcctaataa
1440 ccttgacctt gcttgttgtta ttccgtctatc tcgagggcaat tccaatgta ttaaccggagc
1500 tatcatctatc tacaataata atttctatgt ttttatatgt ttgttaacaat aatgaattaa
1560 tagaaagcttc gataaaatg c gcttgatatg gagatgttcat gataatatcag actaatgggat
1620 ttacgctgtt ggtttctttg acctaaacctta aatcaccttt agcgacctca ttatataaat
1680 ctgttatatga tgttgttgctg ttaattctttt ctagctttgc ttctaagtct tgattatatagg
1740 tatatatattt ttcaaaatct tgcgagaacca attggaagtg tttaataaaa agtttatattt
1800 cgtttttccaag ggaatgcggat agcggatgtt tactgtccctg ttgttgccaat aaagtttgtt
1860 gagaaaaataat gttcttttgttt aagattgttt tttagactac aattttattt tgaagggtgt
1920 tgaattctcat ttctttttca tgtttggggg gatttttagt cattttgttt tgaagtcatct
1940 ctttttttct cttcaattca

<210> 4

<211> 651
 <212> PRT
 <213> *Pasteurella multocida*

<400> 4

Met Lys Arg Lys Lys Glu Met Thr Gln Lys Gln Met Thr Lys Asn Pro
 1 5 10 15
 Pro Gln His Glu Lys Glu Asn Glu Leu Asn Thr Phe Gln Asn Lys Ile
 20 25 30
 Asp Ser Leu Lys Thr Thr Leu Asn Lys Asp Ile Ile Ser Gln Gln Thr
 35 40 45
 Leu Leu Ala Lys Gln Asp Ser Lys His Pro Leu Ser Ala Ser Leu Glu
 50 55 60
 Asn Glu Asn Lys Leu Leu Leu Lys Gln Leu Gln Leu Val Leu Gln Glu
 65 70 75 80
 Phe Glu Lys Ile Tyr Thr Tyr Asn Gln Ala Leu Glu Ala Lys Leu Glu
 85 90 95
 Lys Asp Lys Gln Thr Thr Ser Ile Thr Asp Leu Tyr Asn Glu Val Ala
 100 105 110
 Lys Ser Asp Leu Gly Leu Val Lys Glu Thr Asn Ser Val Asn Pro Leu
 115 120 125
 Val Ser Ile Ile Met Thr Ser His Asn Thr Ala Gln Phe Ile Glu Ala
 130 135 140
 Ser Ile Asn Ser Leu Leu Leu Gln Thr Tyr Lys Asn Ile Glu Ile Ile
 145 150 155 160
 Ile Val Asp Asp Asp Ser Ser Asp Asn Thr Phe Glu Ile Ala Ser Arg
 165 170 175
 Ile Ala Asn Thr Thr Ser Lys Val Arg Val Phe Arg Leu Asn Ser Asn
 180 185 190
 Leu Gly Thr Tyr Phe Ala Lys Asn Thr Gly Ile Leu Lys Ser Lys Gly
 195 200 205
 Asp Ile Ile Phe Phe Gln Asp Ser Asp Asp Val Cys His His Glu Arg
 210 215 220
 Ile Glu Arg Cys Val Asn Ile Leu Leu Ala Asn Lys Glu Thr Ile Ala
 225 230 235 240
 Val Arg Cys Ala Tyr Ser Arg Leu Ala Pro Glu Thr Gln His Ile Ile
 245 250 255
 Lys Val Asn Asn Met Asp Tyr Arg Leu Gly Phe Ile Thr Leu Gly Met
 260 265 270
 His Arg Lys Val Phe Gln Glu Ile Gly Phe Phe Asn Cys Thr Thr Lys
 275 280 285
 Gly Ser Asp Asp Glu Phe Phe His Arg Ile Ala Lys Tyr Tyr Gly Lys
 290 295 300

Glu Lys Ile Lys Asn Leu Leu Leu Pro Leu Tyr Tyr Asn Thr Met Arg
 305 310 315 320
 Glu Asn Ser Leu Phe Thr Asp Met Val Glu Trp Ile Asp Asn His Asn
 325 330 335
 Ile Ile Gln Lys Met Ser Asp Thr Arg Gln His Tyr Ala Thr Leu Phe
 340 345 350
 Gln Ala Met His Asn Glu Thr Ala Ser His Asp Phe Lys Asn Leu Phe
 355 360 365
 Gln Phe Pro Arg Ile Tyr Asp Ala Leu Pro Val Pro Gln Glu Met Ser
 370 375 380
 Lys Leu Ser Asn Pro Lys Ile Pro Val Tyr Ile Asn Ile Cys Ser Ile
 385 390 395 400
 Pro Ser Arg Ile Ala Gln Leu Arg Arg Ile Ile Gly Ile Leu Lys Asn
 405 410 415
 Gln Cys Asp His Phe His Ile Tyr Leu Asp Gly Tyr Val Glu Ile Pro
 420 425 430
 Asp Phe Ile Lys Asn Leu Gly Asn Lys Ala Thr Val Val His Cys Lys
 435 440 445
 Asp Lys Asp Asn Ser Ile Arg Asp Asn Gly Lys Phe Ile Leu Leu Glu
 450 455 460
 Glu Leu Ile Glu Lys Asn Gln Asp Gly Tyr Tyr Ile Thr Cys Asp Asp
 465 470 475 480
 Asp Ile Ile Tyr Pro Ser Asp Tyr Ile Asn Thr Met Ile Lys Lys Leu
 485 490 495
 Asn Glu Tyr Asp Asp Lys Ala Val Ile Gly Leu His Gly Ile Leu Phe
 500 505 510
 Pro Ser Arg Met Thr Lys Tyr Phe Ser Ala Asp Arg Leu Val Tyr Ser
 515 520 525
 Phe Tyr Lys Pro Leu Glu Lys Asp Lys Ala Val Asn Val Leu Gly Thr
 530 535 540
 Gly Thr Val Ser Phe Arg Val Ser Leu Phe Asn Gln Phe Ser Leu Ser
 545 550 555 560
 Asp Phe Thr His Ser Gly Met Ala Asp Ile Tyr Phe Ser Leu Leu Cys
 565 570 575
 Lys Lys Asn Asn Ile Leu Gln Ile Cys Ile Ser Arg Pro Ala Asn Trp
 580 585 590
 Leu Thr Glu Asp Asn Arg Asp Ser Glu Thr Leu Tyr His Gln Tyr Arg
 595 600 605
 Asp Asn Asp Glu Gln Gln Thr Gln Leu Ile Met Glu Asn Gly Pro Trp
 610 615 620

Gly Tyr Ser Ser Ile Tyr Pro Leu Val Lys Asn His Pro Lys Phe Thr
 625 630 635 640

Asp Leu Ile Pro Cys Leu Pro Phe Tyr Phe Leu
 645 650

<210> 5
 <211> 1854
 <212> DNA
 <213> *Pasteurella multocida*

<400> 5
 atgagcttat ttaaactgct tactgagcta ttaagtacag gaaactataa agatgcacta 60
 actctatatg aaaatatagc taaaatttat gggttcagaaa gccttggttaa atataatatt 120
 gatatatgta aaaaaaatat aacacaatca aaaagtaata aaatagaaga agataatatt 180
 tctggagaaa acaaatcttc agtatcaata aaagatctat ataacgaaat aagcaatagt 240
 gaattagggg ttacaaaaga aagactagga gccccccctc tagtcagtat tataatgact 300
 tctcataata cagaaaaatt cattgaagcc tcaattaatt cactattatt gcaaacatac 360
 aataacttag aagttatcgt tgtagatgat tatagcacag ataaaacatt tcagatcgca 420
 tccagaatag caaactctac aagtaaagta aaaacattcc gattaaactc aaatctaggg 480
 acatactttg cgaaaaatac aggaatttta aagtctaaag gagatattat tttctttcag 540
 gatagcgtg atgtatgtca ccatgaaaga atcgaaagat gtgttaatgc attattatcg 600
 aataaagata atatagctgt tagatgtgca tattctagaa taaatctaga aacacaaaat 660
 ataataaaag ttaatgataa taaatacaaa ttaggattaa taactttagg cgtttataga 720
 aaagtattta atgaaattgg tttttttaac tgcacaacca aagcatcgga tgatgaattt 780
 tatcatagaa taattaaata ctatggtaaa aataggataa ataacttatt tctaccactg 840
 tattataaca caatgcgtga agattcatta ttttctgata tgggtgagtg ggtagatgaa 900
 aataatataa agcaaaaaac ctctgatgct agacaaaatt atctccatga attccaaaaa 960
 atacacaatg aaaggaaatt aaatgaatta aaagagattt ttagctttcc tagaattcat 1020
 gacgccttac ctatatcaaa agaaatgagt aagctcagca accctaaaat tcctgtttat 1080
 ataaatataat gctcaatacc ttcaagaata aaacaacttc aatacactat tggagtacta 1140
 aaaaaccaat gcgatcattt tcatatttat ctgtatggat atccagaagt acctgatttt 1200
 ataaaaaac tagggaataa agcgaccgtt attaattgtc aaaacaaaaa tgagtctatt 1260
 agagataatg gaaagtttat tctattagaa aaacttataa aggaaaataa agatggatat 1320
 tatataactt gtgatgatga tatccggtat cctgctgact acataaacac tatgataaaa 1380
 aaaattaata aatacaatga taaagcagca attggattac atggtgttat attcccaagt 1440
 agagtcaaca agtatttttc atcagacaga attgtctata attttcaaaa acctttagaa 1500
 aatgatactg ctgtaaatat attaggaact ggaactgttg ccttttagagt atctattttt 1560
 aataaatttt ctctatctga ttttgagcat cctggcatgg tagatatcta tttttctata 1620
 ctatgtaaga aaaacaatat actccaagtt tgtatatcac gaccatcgaa ttggctaaca 1680
 gaagataaca aaacactga gaccttattt catgaattcc aaaatagaga tgaaatacaa 1740
 agtaaactca ttatttcaaa caacccttgg ggatactcaa gtatatatcc attattaaat 1800
 aataatgcta attattctga acttattccg tgtttatctt tttataacga gtaa 1854

<210> 6
 <211> 617
 <212> PRT
 <213> *Pasteurella multocida*

<400> 6

Met Ser Leu Phe Lys Arg Ala Thr Glu Leu Phe Lys Ser Gly Asn Tyr
 1 5 10 15
 Lys Asp Ala Leu Thr Leu Tyr Glu Asn Ile Ala Lys Ile Tyr Gly Ser
 20 25 30
 Glu Ser Leu Val Lys Tyr Asn Ile Asp Ile Cys Lys Lys Asn Ile Thr
 35 40 45
 Gln Ser Lys Ser Asn Lys Ile Glu Glu Asp Asn Ile Ser Gly Glu Asn
 50 55 60
 Lys Phe Ser Val Ser Ile Lys Asp Leu Tyr Asn Glu Ile Ser Asn Ser
 65 70 75 80
 Glu Leu Gly Ile Thr Lys Glu Arg Leu Gly Ala Pro Pro Leu Val Ser
 85 90 95
 Ile Ile Met Thr Ser His Asn Thr Glu Lys Phe Ile Glu Ala Ser Ile
 100 105 110
 Asn Ser Leu Leu Leu Gln Thr Tyr Asn Asn Leu Glu Val Ile Val Val
 115 120 125
 Asp Asp Tyr Ser Thr Asp Lys Thr Phe Gln Ile Ala Ser Arg Ile Ala
 130 135 140
 Asn Ser Thr Ser Lys Val Lys Thr Phe Arg Leu Asn Ser Asn Leu Gly
 145 150 155 160
 Thr Tyr Phe Ala Lys Asn Thr Gly Ile Leu Lys Ser Lys Gly Asp Ile
 165 170 175
 Ile Phe Phe Gln Asp Ser Asp Asp Val Cys His His Glu Arg Ile Glu
 180 185 190
 Arg Cys Val Asn Ala Leu Leu Ser Asn Lys Asp Asn Ile Ala Val Arg
 195 200 205
 Cys Ala Tyr Ser Arg Ile Asn Leu Glu Thr Gln Asn Ile Ile Lys Val
 210 215 220
 Asn Asp Asn Lys Tyr Lys Leu Gly Leu Ile Thr Leu Gly Val Tyr Arg
 225 230 235 240
 Lys Val Phe Asn Glu Ile Gly Phe Phe Asn Cys Thr Thr Lys Ala Ser
 245 250 255
 Asp Asp Glu Phe Tyr His Arg Ile Ile Lys Tyr Tyr Gly Lys Asn Arg
 260 265 270
 Ile Asn Asn Leu Phe Leu Pro Leu Tyr Tyr Asn Thr Met Arg Glu Asp
 275 280 285
 Ser Leu Phe Ser Asp Met Val Glu Trp Val Asp Glu Asn Asn Ile Lys
 290 295 300
 Gln Lys Thr Ser Asp Ala Arg Gln Asn Tyr Leu His Glu Phe Gln Lys
 305 310 315 320

Ile His Asn Glu Arg Lys Leu Asn Glu Leu Lys Glu Ile Phe Ser Phe
 325 330 335
 Pro Arg Ile His Asp Ala Leu Pro Ile Ser Lys Glu Met Ser Lys Leu
 340 345 350
 Ser Asn Pro Lys Ile Pro Val Tyr Ile Asn Ile Cys Ser Ile Pro Ser
 355 360 365
 Arg Ile Lys Gln Leu Gln Tyr Thr Ile Gly Val Leu Lys Asn Gln Cys
 370 375 380
 Asp His Phe His Ile Tyr Leu Asp Gly Tyr Pro Glu Val Pro Asp Phe
 385 390 395 400
 Ile Lys Lys Leu Gly Asn Lys Ala Thr Val Ile Asn Cys Gln Asn Lys
 405 410 415
 Asn Glu Ser Ile Arg Asp Asn Gly Lys Phe Ile Leu Leu Glu Lys Leu
 420 425 430
 Ile Lys Glu Asn Lys Asp Gly Tyr Tyr Ile Thr Cys Asp Asp Asp Ile
 435 440 445
 Arg Tyr Pro Ala Asp Tyr Ile Asn Thr Met Ile Lys Lys Ile Asn Lys
 450 455 460
 Tyr Asn Asp Lys Ala Ala Ile Gly Leu His Gly Val Ile Phe Pro Ser
 465 470 475 480
 Arg Val Asn Lys Tyr Phe Ser Ser Asp Arg Ile Val Tyr Asn Phe Gln
 485 490 495
 Lys Pro Leu Glu Asn Asp Thr Ala Val Asn Ile Leu Gly Thr Gly Thr
 500 505 510
 Val Ala Phe Arg Val Ser Ile Phe Asn Lys Phe Ser Leu Ser Asp Phe
 515 520 525
 Glu His Pro Gly Met Val Asp Ile Tyr Phe Ser Ile Leu Cys Lys Lys
 530 535 540
 Asn Asn Ile Leu Gln Val Cys Ile Ser Arg Pro Ser Asn Trp Leu Thr
 545 550 555 560
 Glu Asp Asn Lys Asn Thr Glu Thr Leu Phe His Glu Phe Gln Asn Arg
 565 570 575
 Asp Glu Ile Gln Ser Lys Leu Ile Ile Ser Asn Asn Pro Trp Gly Tyr
 580 585 590
 Ser Ser Ile Tyr Pro Leu Leu Asn Asn Asn Ala Asn Tyr Ser Glu Leu
 595 600 605
 Ile Pro Cys Leu Ser Phe Tyr Asn Glu
 610 615

<210> 7
 <211> 565
 <212> PRT

<213> *Pasteurella multocida*

<400> 7

```

Met Ser Leu Phe Lys Arg Ala Thr Glu Leu Phe Lys Ser Gly Asn Tyr
1      5      10      15
Lys Asp Ala Leu Thr Leu Tyr Glu Asn Ile Ala Lys Ile Tyr Gly Ser
20      25      30
Glu Ser Leu Val Lys Tyr Asn Ile Asp Ile Cys Lys Lys Asn Ile Thr
35      40      45
Gln Ser Lys Ser Asn Lys Ile Glu Glu Asp Asn Ile Ser Gly Glu Asn
50      55      60
Lys Phe Ser Val Ser Ile Lys Asp Leu Tyr Asn Glu Ile Ser Asn Ser
65      70      75      80
Glu Leu Gly Ile Thr Lys Glu Arg Leu Gly Ala Pro Pro Leu Val Ser
85      90      95
Ile Ile Met Thr Ser His Asn Thr Glu Lys Phe Ile Glu Ala Ser Ile
100     105     110
Asn Ser Leu Leu Leu Gln Thr Tyr Asn Leu Glu Val Ile Val Val Asp
115     120     125
Asp Tyr Ser Thr Asp Lys Thr Phe Gln Ile Ala Ser Arg Ile Ala Asn
130     135     140
Ser Thr Ser Lys Val Lys Thr Phe Arg Leu Asn Ser Asn Leu Gly Thr
145     150     155     160
Tyr Phe Ala Lys Asn Thr Gly Ile Leu Lys Ser Lys Gly Asp Ile Ile
165     170     175
Phe Phe Gln Ser Asp Asp Val Cys His His Glu Arg Ile Glu Arg Cys
180     185     190
Val Asn Ala Leu Leu Ser Asn Lys Asp Asn Ile Ala Val Arg Cys Ala
195     200     205
Tyr Ser Arg Ile Asn Leu Glu Thr Gln Asn Ile Ile Lys Val Asn Asp
210     215     220
Asn Lys Tyr Lys Leu Gly Leu Ile Thr Leu Gly Val Tyr Arg Lys Val
225     230     235     240
Phe Asn Glu Ile Gly Phe Phe Asn Cys Thr Thr Lys Ala Ser Asp Asp
245     250     255
Glu Phe Tyr His Arg Ile Ile Lys Tyr Tyr Gly Lys Asn Arg Ile Asn
260     265     270
Asn Leu Phe Leu Pro Leu Tyr Tyr Asn Thr Met Arg Glu Asp Ser Leu
275     280     285
Phe Ser Asp Met Val Glu Trp Val Asp Glu Asn Asn Ile Lys Gln Lys
290     295     300
Thr Ser Asp Ala Arg Gln Asn Tyr Leu His Glu Phe Gln Lys Ile His

```

305 310 315 320
 Asn Glu Arg Lys Leu Asn Glu Leu Lys Glu Ile Phe Ser Phe Pro Arg
 325 330 335
 Ile His Asp Ala Leu Pro Ile Ser Lys Glu Met Ser Lys Leu Ser Asn
 340 345 350
 Pro Lys Ile Pro Val Tyr Ile Asn Ile Cys Ser Ile Pro Ser Arg Ile
 355 360 365
 Lys Gln Leu Gln Tyr Thr Ile Gly Val Leu Lys Asn Gln Cys Asp His
 370 375 380
 Phe His Ile Tyr Leu Asp Gly Tyr Pro Glu Val Pro Asp Phe Ile Lys
 385 390 395 400
 Lys Leu Gly Asn Lys Ala Thr Val Ile Asn Cys Gln Asn Lys Asn Glu
 405 410 415
 Ser Ile Arg Asp Asn Gly Lys Phe Ile Leu Leu Glu Lys Leu Ile Lys
 420 425 430
 Glu Asn Lys Asp Gly Tyr Tyr Ile Thr Cys Asp Asp Asp Ile Arg Tyr
 435 440 445
 Pro Ala Asp Tyr Thr Asn Thr Met Ile Lys Lys Ile Asn Lys Tyr Asn
 450 455 460
 Asp Lys Ala Ala Ile Gly Leu His Gly Val Ile Phe Pro Ser Arg Val
 465 470 475 480
 Asn Lys Tyr Phe Ser Ser Asp Arg Ile Val Tyr Asn Phe Gln Lys Pro
 485 490 495
 Leu Glu Asn Asp Thr Ala Val Asn Ile Leu Gly Thr Gly Thr Val Ala
 500 505 510
 Phe Arg Val Ser Ile Phe Asn Lys Phe Ser Leu Ser Asp Phe Glu His
 515 520 525
 Pro Gly Met Val Asp Ile Tyr Phe Ser Ile Leu Cys Lys Lys Asn Asn
 530 535 540
 Ile Leu Gln Val Cys Ile Ser Arg Pro Ser Asn Trp Leu Thr Glu Asp
 545 550 555 560
 Asn Lys Asn Thr Glu
 565

<210> 8
 <211> 538
 <212> PRT
 <213> Pasteurella multocida

<400> 8

Ser Asn Ser Glu Leu Gly Ile Thr Lys Glu Arg Leu Gly Ala Pro Pro
 1 5 10 15
 Leu Val Ser Ile Ile Met Thr Ser His Asn Thr Glu Lys Phe Ile Glu
 20 25 30

Ala Ser Ile Asn Ser Leu Leu Leu Gln Thr Tyr Asn Leu Glu Val Ile
 35 40 45
 Val Val Asp Asp Tyr Ser Thr Asp Lys Thr Phe Gln Ile Ala Ser Arg
 50 55 60
 Ile Ala Asn Ser Thr Ser Lys Val Lys Thr Phe Arg Leu Asn Ser Asn
 65 70 75 80
 Leu Gly Thr Tyr Phe Ala Lys Asn Thr Gly Ile Leu Lys Ser Lys Gly
 85 90 95
 Asp Ile Ile Phe Phe Gln Ser Asp Asp Val Cys His His Glu Arg Ile
 100 105 110
 Glu Arg Cys Val Asn Ala Leu Leu Ser Asn Lys Asp Asn Ile Ala Val
 115 120 125
 Arg Cys Ala Tyr Ser Arg Ile Asn Leu Glu Thr Gln Asn Ile Ile Lys
 130 135 140
 Val Asn Asp Asn Lys Tyr Lys Leu Gly Leu Ile Thr Leu Gly Val Tyr
 145 150 155 160
 Arg Lys Val Phe Asn Glu Ile Gly Phe Phe Asn Cys Thr Thr Lys Ala
 165 170 175
 Ser Asp Asp Glu Phe Tyr His Arg Ile Ile Lys Tyr Tyr Gly Lys Asn
 180 185 190
 Arg Ile Asn Asn Leu Phe Leu Pro Leu Tyr Tyr Asn Thr Met Arg Glu
 195 200 205
 Asp Ser Leu Phe Ser Asp Met Val Glu Trp Val Asp Glu Asn Asn Ile
 210 215 220
 Lys Gln Lys Thr Ser Asp Ala Arg Gln Asn Tyr Leu His Glu Phe Gln
 225 230 235 240
 Lys Ile His Asn Glu Arg Lys Leu Asn Glu Leu Lys Glu Ile Phe Ser
 245 250 255
 Phe Pro Arg Ile His Asp Ala Leu Pro Ile Ser Lys Glu Met Ser Lys
 260 265 270
 Leu Ser Asn Pro Lys Ile Pro Val Tyr Ile Asn Ile Cys Ser Ile Pro
 275 280 285
 Ser Arg Ile Lys Gln Leu Gln Tyr Thr Ile Gly Val Leu Lys Asn Gln
 290 295 300
 Cys Asp His Phe His Ile Tyr Leu Asp Gly Tyr Pro Glu Val Pro Asp
 305 310 315 320
 Phe Ile Lys Lys Leu Gly Asn Lys Ala Thr Val Ile Asn Cys Gln Asn
 325 330 335
 Lys Asn Glu Ser Ile Arg Asp Asn Gly Lys Phe Ile Leu Leu Glu Lys
 340 345 350

Leu Ile Lys Glu Asn Lys Asp Gly Tyr Tyr Ile Thr Cys Asp Asp Asp
 355 360 365
 Ile Arg Tyr Pro Ala Asp Tyr Thr Asn Thr Met Ile Lys Lys Ile Asn
 370 375 380
 Lys Tyr Asn Asp Lys Ala Ala Ile Gly Leu His Gly Val Ile Phe Pro
 385 390 395 400
 Ser Arg Val Asn Lys Tyr Phe Ser Ser Asp Arg Ile Val Tyr Asn Phe
 405 410 415
 Gln Lys Pro Leu Glu Asn Asp Thr Ala Val Asn Ile Leu Gly Thr Gly
 420 425 430
 Thr Val Ala Phe Arg Val Ser Ile Phe Asn Lys Phe Ser Leu Ser Asp
 435 440 445
 Phe Glu His Pro Gly Met Val Asp Ile Tyr Phe Ser Ile Leu Cys Lys
 450 455 460
 Lys Asn Asn Ile Leu Gln Val Cys Ile Ser Arg Pro Ser Asn Trp Leu
 465 470 475 480
 Thr Glu Asp Asn Lys Asn Thr Glu Thr Leu Phe His Glu Phe Gln Asn
 485 490 495
 Arg Asp Glu Ile Gln Ser Lys Leu Ile Ile Ser Asn Asn Pro Trp Gly
 500 505 510
 Tyr Ser Ser Ile Tyr Pro Leu Leu Asn Asn Asn Ala Asn Tyr Ser Glu
 515 520 525
 Leu Ile Pro Cys Leu Ser Phe Tyr Asn Glu
 530 535

<210> 9

<211> 1864

<212> DNA

<213> Artificial Sequence

<220>

<223> Pasteurella multocida heparosan synthase sequence gene-optimized for expression in E. coli

<400> 9

ggtaccgagc ctgtttaaac gtgcgaccga actgttcaaa agcggtaact ataaagatgc	60
gctgaccctg tatgaaaata ttgcgaaaat ttatggtagc gaaagcctgg ttaaatataa	120
catcgatatc tgcaagaaaa acattaccca gagcaaaagc aacaaaattg aagaagataa	180
cattagcggc gaaaacaaat ttagcgtgag cattaagat ctgtataacg aaattagcaa	240
cagcgaactg ggcattacca aagaacgcct gggcgcgccg ccgctggtta gcattattat	300
gaccagccac aacaccgaaa aattttattga agcgagcatc aatagcctgc tgctgcagac	360
ctataacaat ctggaagtga ttgtttgtga tgattatagc accgataaaa cttttcagat	420
tgcaagccgt atcgaaaca gcaccagcaa agttaaacc tttgcctga atagcaacct	480
gggcacctat ttgcaaaaa acaccggtat tctgaaaagc aaaggcgata tcattttctt	540
tcaggatagc gatgatgtgt gccatcatga acgcattgaa cgctgtgtga acgcgctgct	600
gagcaataaa gataacattg cggcgcgctg cgcctatagc cgtattaacc tggaaacca	660
gaacattatc aaagttaacg ataacaata taaactgggt ctgattaccc tgggcgtgta	720

780 tcgtgaagtt tttaatgaaa ttgcctttt caattgcacc accaaagcaa gcgatgatga
 840 attctatcat cgtattatta aatatatttg caaaaaccgt atcaacaacc tgttccctgc
 900 gctgtattat aacacccatgc gtgaagatag cctgttttag gatatgttgg aatgggttgg
 960 tgaataatac attaacaaga aacccagga tgcgcgcag aactatctgc atgaattccc
 1020 gaaattcat aacgaacgta aactgaacga actgaaga aatctcagc ttccgcgtat
 1080 tcaagatgcg ctgcgcgatta gcaagaataat gagcaaaactg agcaaacccga aatcccggt
 1140 gtatatcaac atttgcagcga tattaaacag ctgcagatat ccatitgtgt
 1200 gctgaaaaaa cagtgcgatac attttcatat ctatctgat gctatatccgg aagtccctga
 1260 ttattataa aacttggga acaagcaac cgtattaac tgcagagaa aaaaagaaag
 1320 catctgtgat aacgcgaat ttattctgtc ggaaaaaactg attaagaaa acaagatgg
 1380 ttattatatt accctgcgata atgatattcg ttatcccgcg gattatatata acaaccatgat
 1440 taagaaaaat aacaatatata acgatataagc ggcgatttgc ctgcatttgcg ttatctttccc
 1500 gagccgcgtg aacaaatat tttagcagcga tcgatatctg tataattttc agaaaccgct
 1560 ggaataatgat accgcgtgga atattcttgg caccgcgcac gttgcgttcc gttgatgat
 1620 tttaataaa tttagccctga gtagatttcga acatcccggc atgtgttgata tttaatttag
 1680 catctctgtc aagaaaaaaca acattctgca ggttttgcat agccgtccca gcaatttgc
 1740 gaccgagat aacaaaaata ccgaaacccct gttccagaa ttccagaaac gtgatgaata
 1800 ccagagcaaa ctgattatta gcaacaatcc gttggggttat agcagcatct atccgcgtct
 1860 gaaacaacaac gcaaatata gcgaaatgat tccgttcctg agcttttata atgaataagg
 1864 atcc

<210> 10
 <211> 1864
 <212> DNA
 <213> Artificial Sequence
 <220>
 <223> Pasteurella multocida heparosan synthase sequence gene-optimized
 for expression in E. coli

60 gttacagagc ctgtttaaac gtcgcgaccga actgtttaa agcggcgaact ataagatgc
 120 gctgacccctg tatgaaaaaa atgcgcgaat ttatggcagc gaaagccctg ttgaatatcaa
 180 catcgtatct tgcagaataa acatcacccca gagcaaaaagc acaaaaactg aagaagataa
 240 catcagcgcc gaaaaaataa tttagcgttga cattaaaagt ctgtataacg aatttagcaa
 300 cagcgaactg gtcattatac aagaacgtct ggcgcgcgcg ccgcctgttga gcatatttat
 360 gaccagcccat aacacccga aatttatga agcagatatt aacagccctg tgcctgcagagc
 420 ctatacaaac ctggaagatga ttgttgggtga ttgattatagc accgatataa cctttcagat
 480 ttgcagccgt attcgcgaca aacagcaaa agtgaaaaac cccctttctcgtttcga acagcaacc
 540 gggcaccatat tttcgcga aaaaaaaca aacccgcgat tctgaaaagc aaagcagata ttatctttt
 600 ccagggataga gctgatatgttgtt gttgtatcccat acgttatatga acgttcgttga acgctcgtc
 660 gagaacaaga gataacaa gtttcacaa gtttcacaa gtttcacaa gtttcacaa gtttcacaa
 720 gaaacattat aagtgacaa gtttcacaa gtttcacaa gtttcacaa gtttcacaa gtttcacaa
 780 gctgtattat aacacccatgc gtgaagatag cctgttttag gatatgttgg aatgggttgg

60 atgggtaccct cactgtttaa acgtgcgtacg gaacttttta aagcgggaaa ctacaagaat
 120 gctcttaacat tgtacgcaaaa catcgcgccaaa atctatgcca ggcatactct ggttaaatac
 180 aaacatctcag gagaataaaca aatttcttgtt tcaatccaag ag atttatataa cgaataatga
 240 aaacatctcag gagaataaaca aatttcttgtt tcaatccaag ag atttatataa cgaataatga
 300 aatcttgcaat tgggcatac caaagaacgg ttagggcgac cgctcttgtgt gttctatatc
 360 atgacatcac ataaacacggg aaaaatttatc gaagccagca tcaactctc gctttttag
 420 acatacaaca acccttgagc catcgttgtgt gatgtattact ctacagataa aacgttttcaa
 480 atcctcctcaa gaactgcaca aacacaaac aaagtataa cgttctcgtt ttacacgaat
 540 ttgggcacacat accttgctaa aaacacgggc atcttaaaaa gcaaaaggag tatacatttcc
 600 ttctcaggatt ctgagtgtgt tgcctcat gaagaagatg aacgctgtgt aaaaagctgt
 660 ctgagcgaaca acaataatata tatatctgacgtt ctctcagctc aacgagcctc acaaaaaca
 720 caaacacaca acaataaaca aacataaaca cgaataaaca tacaataatgg gcttggggtt
 780 tctgtaaacg tgttaaacg aatcgggttt ttcaatttga atgaatttga atgaatttga
 840 gaatttttaa ccaataatga tcaataaaca ccaataaaca gcaatttga atgaatttga
 900 tctgttgttc tcaataaaca acaataaaca atgaatttga atgaatttga atgaatttga
 960 gtagaataac acatacaaca acatacaaca acatacaaca acatacaaca acatacaaca
 1020 caatacaaca acatacaaca acatacaaca acatacaaca acatacaaca acatacaaca
 1080 attcattgat cgcctgcctat tatatcctca aaaaaagaa acatgcacga atgccttcaac
 11080 tcccc

<210> 11
 <211> 1860
 <212> DNA
 <213> Artificial sequence
 <220>
 <223> Pasteurella multocida HS sequence gene-optimized for expression in Bacillus

960 tgaataaaca acatacaaca atgaatacga tgcgcgtcag aacatacctg atgaatttcc
 1020 gaaatacctat aacgaacgta aactgaacga actgaagaat atttttagct ttccgcgtat
 1080 tcatgtatgcg ctgcggcgtta gacgaagaat gagcaaacct agcaaacccg aatttccggt
 1140 gtatatatac atttgcagca tctccgagccg tatataaaca gctgcagataa ccatgtgcgt
 1200 gctgaataaac cagtgcgcatc atttctatat ttatcttgat ggcatacgg aagtgcggga
 1260 ttatatcaag aaactgtggc aacaagcga cgtgatataa cgtgatataa cgtgatataa
 1320 catcctgtgat aacgagcaaat tcatcctcgt ggaataaactg atcaagaata acaagatgtg
 1380 ctactacatc accctgcgcat atgatatatc ggtatccggc gatataca acaaccatgat
 1440 taagaataac acaataaca acgaataaag cgcgatgtgc ctcgcagtgc tgcatttttccc
 1500 gagcgcgtgtg aacataatata ttatgcagcga tcatgttgtg tataaacttc agaaacgcgt
 1560 ggaataacgat accgcgctga acatcttggg caccggcgacc cgtgcgtttc gttgtgagccat
 1620 tttaatacaaa tttagcctga gcgaatttga acatcttga ggtgtgcatt agcgcgtcga gcaacatgct
 1680 catcttgtgc aagaataaaca acatacttga acatcttga ggtgtgcatt agcgcgtcga gcaacatgct
 1740 gaccgaagat aacaataaaca cccgaacccct gtttcaatga aattcagaacc gtgatgaat
 1800 tcagagcaaaa ctgatatata gcaacaaccc gttgggcttat agcagcatat atccgcgtgt
 1860 gaaacaacaac gcgaactata tccgtgcctg agcttttata acgaataaag
 1864 atcc

gttacatca acatttgcct aattccgctt cgcatacaac aattacagta cacaatcggg
 1140
 gtgttgaaaa accagtgtga tcattttccat atctaatgtg atggtatcc ggaagtcc
 1200
 gatttatca aaaaattggg aacaacaagca acgtggtatca acttgccaaaa caaaaacgaa
 1260
 agcatcagag ataacggcga atttatccct ttgaaaaaat tgatcaaaag aacaagaat
 1320
 gatatcata tcacatgtga tgaatgatat cgtatatccct cggattatat taatacagatg
 1380
 attaagaaaa ttaacaataa cagcgatcg gccgtcagtg agttatcttt
 1440
 cgtctcgtg tgaacaataa cttttcaagc gatcggatcg tctacaacct tcagaacct
 1500
 ttgaaaaacg atacagcagt aaacatcttg ggcacaagaa cgttcgctt tagagtata
 1560
 atcttaaca aattttctc tgcagatctt gaacatcccg gcatgtgtga tatctactt
 1620
 agcatccctg gcaagaaaaa taacatccct caagtgtgtga tctcaagacc tagcaattgg
 1680
 ctgacagaa agatacaaaa cacaagaacg ctttttcaatg aatttcaaaa cgcgagtga
 1740
 atccagagca aacttatcat ccttaacaac ccgtggggat attcttcaat ctaccccttg
 1800
 ctgaaacaaca acgcaaaacta ctgaacctg atcccgtgtc ttagctttta taacgaataa
 1860